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Abstract
ABSTRACT EVALUATING RISKS FROM ANTIBACTERIAL MEDICATION THERAPY USING AN
OBSERVATIONAL PRIMARY CARE DATABASE Sharon B. Meropol Joshua P. Metlay Virtually everyone
in the U.S. is exposed to antibacterial drugs at some point in their lives. It is important to understand the
benefits and risks related to these medications with nearly universal public exposure. Most information on
antibacterial drug-associated adverse events comes from spontaneous reports. Without an unexposed control
group, it is impossible to know the real risks for treated vs. untreated patients. We used an electronic medical
record database to select a cohort of office visits for non-bacterial acute respiratory tract infections (excluding
patients with pneumonia, sinusitis, or acute exacerbations of chronic bronchitis), and compared outcomes of
antibacterial drug-exposed vs. -unexposed patients. By limiting our assessment to visits with acute nonspecific
respiratory infections, we promoted comparability between exposed and unexposed patients. To further
control for confounding by indication and practice, we explored methods to promote further comparability
between exposure groups. Our rare outcome presented an additional analytic challenge. Antibacterial drug
prescribing for acute nonspecific respiratory infections decreased over the study period, but, in contrast to the
U.S., broad spectrum antibacterial prescribing remained low. Conditional fixed effects linear regression
provided stable estimates of exposure effects on rare outcomes; results were similar to those using more
traditional methods for binary outcomes. Patients with acute nonspecific respiratory infections treated with
antibacterial drugs were not at increased risk of severe adverse events compared to untreated patients. Patients
with acute nonspecific respiratory infections exposed to antibacterials had a small decreased risk of
pneumonia hospitalizations vs. unexposed patients. This very small measurable benefit of antibacterial drug
therapy for acute nonspecific respiratory infections at the patient level must be weighed against the public
health risk of emerging antibacterial resistance. Our data provide valuable point estimates of risks and benefits
that can be used to inform future decision analysis and guideline recommendations for patients with acute
nonspecific respiratory infections. Ultimately, improved point-of-care diagnostic testing may help direct
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ABSTRACT 
EVALUATING RISKS FROM ANTIBACTERIAL MEDICATION THERAPY  
USING AN OBSERVATIONAL PRIMARY CARE DATABASE 
Sharon B. Meropol 
Joshua P. Metlay 
Virtually everyone in the U.S. is exposed to antibacterial drugs at some point in their lives.  It is 
important to understand the benefits and risks related to these medications with nearly universal 
public exposure.  Most information on antibacterial drug-associated adverse events comes from 
spontaneous reports.  Without an unexposed control group, it is impossible to know the real risks 
for treated vs. untreated patients.  We used an electronic medical record database to select a 
cohort of office visits for non-bacterial acute respiratory tract infections (excluding patients with 
pneumonia, sinusitis, or acute exacerbations of chronic bronchitis), and compared outcomes of 
antibacterial drug-exposed vs. -unexposed patients.  By limiting our assessment to visits with 
acute nonspecific respiratory infections, we promoted comparability between exposed and 
unexposed patients.  To further control for confounding by indication and practice, we explored 
methods to promote further comparability between exposure groups.  Our rare outcome 
presented an additional analytic challenge.  Antibacterial drug prescribing for acute nonspecific 
respiratory infections decreased over the study period, but, in contrast to the U.S., broad 
spectrum antibacterial prescribing remained low.  Conditional fixed effects linear regression 
provided stable estimates of exposure effects on rare outcomes; results were similar to those 
using more traditional methods for binary outcomes.  Patients with acute nonspecific respiratory 
infections treated with antibacterial drugs were not at increased risk of severe adverse events 
compared to untreated patients.  Patients with acute nonspecific respiratory infections exposed to 
antibacterials had a small decreased risk of pneumonia hospitalizations vs. unexposed patients. 
This very small measurable benefit of antibacterial drug therapy for acute nonspecific respiratory 
infections at the patient level must be weighed against the public health risk of emerging 
antibacterial resistance.  Our data provide valuable point estimates of risks and benefits that can 
be used to inform future decision analysis and guideline recommendations for patients with acute 
vii 
nonspecific respiratory infections.  Ultimately, improved point-of-care diagnostic testing may help 
direct antibacterial drugs to the subset of patients most likely to derive benefit.   
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Chapter 1. Background: assessing drug safety using observational data 
A. ANTIBIOTIC USE IN THE UNITED STATES 
Virtually everyone in the U.S. will be exposed to at least one course of antibacterial 
medications during his/her lifetime.  In the year 2000, persons >age 15 received a total of 
68,481,645 antibacterial prescriptions, averaging 0.31 prescriptions per person per year.[1-4]  It is 
doubtful that the U.S. population has such an extraordinarily high exposure to any other class of 
medications.   
Antibacterials are often prescribed for acute nonspecific respiratory tract infections, 
despite the fact that they are unlikely to be of benefit; adults at approximately half of U.S. office 
visits for acute nonspecific respiratory infections receive antibacterial prescriptions.[5, 6]  At the 
level of the physician-patient encounter, each decision to prescribe an antibacterial medication 
weighs the potential benefits from the medication vs. the potential risks.  For example, the risk of 
a mild, severe, and fatal adverse drug event from amoxicillin is estimated to be approximately 
.056-0.07, 0.0057, and 0.000006 respectively. [7-12]  For acute nonspecific respiratory infections, 
the risk of an adverse drug event from a single extra antibacterial drug prescription must often be 
perceived as low, at least lower than the perceived benefit.  Although the perceived risk of an 
adverse event related to antibacterial use may be low, with such a high level of prescribing, the 
population-attributable risk of serious adverse drug events due to this medication class could be 
quite high.   
There are several reasons why this is a particularly timely issue.  
B. Trends in Antibacterial Drug Risk Exposure 
1. Rising antibacterial drug resistance: Antimicrobial resistance is growing.  Up to 30% 
of U.S. Streptococcus pneumoniae isolates are penicillin resistant, pneumococcal 
resistance to penicillin is associated with multi-drug resistance,[13-15] pneumococcal 
macrolide and fluoroquinolone resistance are spreading,[14, 16] and resistance is 
associated with worse clinical outcomes.[17-19]  Most U.S. Staphylococcus aureus is 
now penicillin resistant, and methicillin and vancomycin resistance are increasing.[15]  
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For most pathogens, the spread of antibacterial drug  resistance is influenced by 
selective forces related to the volume and types of community antibacterial drug 
use.[20, 21]  Outpatient antibacterial drug use is the most important driver of this 
escalating resistance, [22]. Our ability to treat patients’ bacterial infections continues 
to erode as the development of new effective antibacterial medications has not kept 
pace with this pattern of increasing antibacterial resistance; our options for treating 
antibacterial infections are shrinking over time.[23-25]  There is increasing urgency 
for new antibacterial drugs to combat this resistance,[23-25] Concomitantly, improved 
methods are needed for utilizing population-based data to detect relatively rare 
adverse event risks in any new medications after drug approval when the volume and 
complexity of exposure to the new drug rapidly increases, discussed further 
below.[26] 
2. Antibacterial drug overuse:  Antibacterial drugs, increasingly broad-spectrum 
antibacterials, are often used to treat conditions for which they would be unlikely to 
be of benefit, such as viral acute respiratory illnesses.[5, 6]  Programs targeting 
providers, patients, and the public can significantly decrease unnecessary 
antibacterial prescribing.[27]  Interventions in Finland[28] and Iceland[29] during the 
1980’s and1990’s, led to decreases in both macrolide-resistant streptococcus in 
Finland, and carriage of resistant pneumococcus in daycare children in Iceland and 
demonstrated that it is possible to reverse the trend toward increasing antibacterial 
resistance.  
 Studies in the U. S. have also demonstrated that multifaceted programs can 
significantly decrease antibacterial drug prescribing, and recent efforts in this country 
to curtail unnecessary antibacterial use have met with some success.[30-36]  During 
the 1990’s, adult antibacterial drug use fell by 23% for upper respiratory infections in 
the U.S., but broad spectrum antibacterial use doubled.  By 2001-2002, 49% of adult 
outpatient visits for conditions for which an antibacterial drug is rarely indicated still 
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received an antibacterial prescription, and 77% of these were for a broad spectrum 
antibacterial drug, an increase of 87% over six years.[6]  More recent data show that 
while antibacterial drug use for acute nonspecific respiratory infections continued to 
fall, by the 2005-2006, about half of U.S. patients over 5 years of age, diagnosed with 
a nonspecific respiratory infection received an antibacterial drug prescription, and 
broad spectrum antibacterial use for acute nonspecific respiratory infections 
continues to rapidly increase.[37]   
3. Antibacterial drugs to treat infections in the elderly:  As the U.S. population ages, 
there will be increasing incidence of conditions that are more common in the older 
age groups; this may influence antibacterial drug use and associated adverse events 
in this particularly vulnerable population.[38]  Takahashi et.al. found that when 
urinary tract infections were treated in the elderly, nursing home residents were more 
likely than nonresidents to experience antibacterial drug-related adverse drug 
events.[39]  Juurlink et.al. showed that elderly patients hospitalized for drug toxicity 
were more than six times as likely to have been treated with trimethoprim 
sulfamethosazole, and those admitted with digoxin toxicity were about twelve times 
more likely to have been treated with clarithromycin.[40]  Gurwitz found that 
antibacterials was the second most frequent class of drugs associated with adverse 
drug events in elderly persons treated in the ambulatory setting, [38] and Budnitz 
et.al. found that trimethoprim-sulfamethoxazole was among the most common 
medications implicated in adverse drug events among elderly patients treated in U.S. 
emergency departments.[41]   
C. Adverse Events Related to Antibacterial Drug Use 
 After U.S. FDA approval, drugs are used for many more patients, for a wider variety of 
indications, and for a more heterogeneous patient population than in pre-approval trials.  The 
importance of post-marketing drug safely surveillance is  increasingly recognized.[42]     
Chapter 1 
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 In the U.S., we have virtually universal exposure to antibacterial medications; on average, 
each adult receives 0.3 antibacterial prescriptions per year.  Antibacterials are also among the 
most common drugs implicated in adverse events.[41, 43, 44]  Many adverse events have been 
reported following antibacterial drug use. Certain antibacterial classes are believed to be 
associated with certain types of adverse events.  For example, antibacterial drugs account for 
55% of reported cutaneous drug eruptions; penicillins and trimethoprim-sulfamethoxazole have 
been most frequently implicated.[45, 46]  The tetracyclines, amoxicillin-clavulanic acid, 
erythromycin, clindamycin, sulfonamides, and trimethoprim sulfamethoxazole are most commonly 
associated with liver injury.[47]  Several cephalosporins and most of the penems are considered 
nephrotoxic. Clostridia difficile colitis has been associated with cephalosporins, clindamycin, and 
during a recent Canadian epidemic, with flouroquinolones.[48]  The most common agents 
associated with photosensitivity are the tetracyclines and sulfonamides.[49]  Beta-lactams, 
imipenum and quinolones have been associated with seizures,[50]  and erythromycin and 
clarithromycin with digoxin toxicity, prolonged QT syndrome and Torsades de Pointes.[51-55]   
 Of particular recent interest are drugs that are suspected of increasing the risk of cardiac 
arrhythmia by prolonging the QTc interval and/or directly causing Torsades de Pointes; 
macrolides and some fluoroquinolones are frequently implicated in adverse events through this 
mechanism.[56]  Also of recent interest are drugs with suspected adverse events related to their 
relationship with the hepatic CYP3A4 pathway.  For example, macrolides are metabolized by the 
CP3A4 pathway and both macrolides and fluoroquinolones are inhibitors of the CYP3A4 pathway 
and thus their interaction with other drugs could heighten the risk of associated adverse 
events.[57, 58]   
 It is notable that most of these associations have been described with case reports and 
cases series; they almost never include a control group measuring adverse events in unexposed 
patients and thus the true absolute and relative risks of adverse events associated with these 
agents remain unknown.   
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 Antibacterials are often prescribed for acute nonspecific respiratory tract infections, 
despite the fact that they are unlikely to be of benefit; adults at about half of U.S. office visits for 
acute nonspecific respiratory tract infections receive antibacterial prescriptions.[5, 37]    As a 
result, using observational data, we can compare adverse event rates between patients treated 
vs. not treated with antibacterial medications for similar conditions.  
D. Data Sources For Estimating Adverse Drug Event Risks  
 There are limited premarketing data regarding population-based antibacterial drug ADE 
risks.  Most premarketing studies include only ~3000 subjects, and are not designed to reveal 
risks <1/1,000 exposed individuals.[26, 59]  There are many examples of antibacterial drug-
associated adverse event risks that became apparent, usually with population-based post-
marketing studies, when more and increasingly medically complex patients experienced drug 
exposure.  For example, erythromycin was shown to be associated with sudden death[60]and 
infantile pyloric stenosis,[61, 62] amoxicillin-clavulanic acid and telithromycin with severe 
hepatotoxicity,[47, 63, 64] and gatifloxacin with dysglycemia.[65]  However, after drug approval, 
there are limited systematic reviews of antibacterial drug risks.  The U.S. Food and Drug 
Administration’s Adverse Event Reporting System database and the U.K’s Drug Safety Research 
Unit’s Prescription-Event Monitoring contain spontaneous reports of adverse drug reactions.[66, 
67]  Without an unexposed control group, it is not possible to distinguish what portion of these 
reported adverse events[68-72] is due to antibacterial drug exposure vs. other risk factors.  In 
2005, Brennan made this critique of his own iatrogenic death estimates in the 1991 Harvard 
Medical Practice Study: “Researchers questioned the real effect on mortality…given the absence 
of control groups to test the counterfactual situation.”[73, 74]  Ecologic data, such as from large 
prescription databases,[75] can examine associations between medication use and other 
parameters, but cannot define individual-level factors related to outcomes from antibacterial drug 
use, or address confounding by health status and other important covariates.[26, 76]   
The growing availability and comprehensiveness of vast ambulatory electronic medical 
records such as the General Practice Research Database (GPRD), and its newer cousin, The 
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Health Improvement Network (THIN), (CDC EPIC, London U.K.),[77-80] linked 
inpatient/outpatient electronic medical records such as those provided by the U.S. EPIC Systems 
Corporation and Eclipsys Corporation, and linked administrative datasets[31, 81, 82] (Kaiser, 
Medicare), are adding breadth and depth to our ability to explore treatment-outcome relationships 
at the individual level with improved ability to adjust for confounders.[26, 83, 84]  Currently, 
approximately 17% of U.S. ambulatory care practices have adopted electronic medical 
records,[85, 86]  and the availability of electronic medical record data is likely to increase rapidly 
over the near future.  The American Recovery and Reinvestment Act of 2009 and recent 
Medicare and Medicaid legislation provides over $20 billion in funding and incentives for 
development and adoption of health information technology by health care providers,[87] some 
hospitals are offering further large incentives for practices to computerize and share data,[86] 
while physician practices may forfeit up to 3% of their Medicare reimbursements if they have not 
adopted an electronic medical record by the year 2014.[88]    Concurrently, the importance of 
enhanced post-marketing drug safety surveillance, is increasingly recognized.[42]   
 
E. Advantages and challenges of using observational data  
 A randomized clinical trial is considered the best way to control confounding, by ensuring 
balance of both measured and unmeasured confounding variables between exposed and 
unexposed subjects,[89] however opportunities and resources to perform large prospective 
randomized trials are limited.  Randomized trials to investigate subtle, rare, or complex effects 
would need to be quite large, would be infeasible to perform for every important research 
question, and are not always ethical.[83]  Observational data, available from a growing number of 
clinical databases, can be used to help ascertain risks of antibacterial medication exposure.  
Longitudinal observational data with individual-level links have the potential to help shed light on 
the outcomes of antibacterial drug use.  However, while observational data can helpfully address 
many of these issues, they do present certain other challenges.  Efficient and resourceful ways of 
Chapter 1 
7 
addressing some of these issues would help us use observational data to yield helpful 
information.   
1. Adjustment for confounding  
Ideally, to estimate the causal effect of antibacterial drug treatment we would want to 
compare the effect of treatment and non-treatment on the same set of subjects at the same time; 
but we cannot.[67, 90]  Randomization balances on unobserved as well as observed covariates 
and thus attempts to select a control group that is the same as the treated (exchangeable).  In 
non-experimental studies, we still seek to find an exchangeable control group but with much 
difficulty because exposures are not randomly assigned.[91] 
Our goal is to estimate the effects of antibacterial drug treatment by comparing treated 
and untreated patients.[67, 92]  In a randomized study, the treatment groups are considered 
comparable prior to treatment.  In non-experimental observational studies, since exposures are 
not randomly assigned patients with different exposures are likely to have other underlying 
differences, measured or unmeasured, Systematic differences between antibacterial drug-users 
and the comparison group, especially confounding by indication, can limit the conclusions.[26, 92, 
93]  With observational data, any apparent temporal relationship between an episode of 
antibacterial drug use and an adverse event may be confounded by patients’ demographic, 
clinical, and prescribing physician characteristics.  Schneeweiss suggested that longitudinal 
observational studies can provide information regarding causal inferences between exposure and 
effect, but potential biases due to differences between subgroups must be explored.[94]   
a) Adjustment for measured confounding  
Visible, recorded pretreatment differences (also called overt bias), can be removed by 
adjustment, exclusion, stratification, matching, and by using propensity scores, most commonly 
by utilizing combinations of some or all of these methods.[91]  For example, comorbidity 
adjustment has been used in the past to help address confounding by indication, most commonly 
to study chronic diseases, [95] and less commonly in the study of acute conditions.[96]  Hunter 
noted that databases with clinical data regarding patients’ co-existing illnesses can be used to 
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address confounding using multivariate techniques and propensity scores.[83]  Chan and 
Shaw[89] advised that evidence from observational data is stronger if any risk persists after 
adjustment for subject demographic characteristics, baseline health status, co-morbid conditions, 
the tendency to be exposed to medical care, and other medication use.  There are many possible 
ways to attempt to adjust for co-morbidity and other patient-related factors; for studies of rare 
outcomes, power becomes problematic when we start adding additional variables.  Using a 
propensity score is a way of efficiently modeling rare outcomes and common treatments.  
Outcomes for treated and untreated patients are compared within strata of patients with a similar 
propensity to have received treatment, or propensity score matching is performed; this maximizes 
the balance of measured covariates between treatment and control groups.[97-99]   
b) Adjustment for unmeasured confounding 
While adjustment for a history of known, measured, and recorded comorbidities can be 
useful, of course it does not adjust for unmeasured confounders.[100]  Unobserved, or 
unmeasured, pretreatment differences (also called hidden bias) must be estimated using other 
methods.[67, 92]  There are several ways to address unmeasured confounding that have been 
used in the past, but experience is limited with their use in GPRD or THIN.   
Studies vary in their degree of sensitivity to unmeasured factors.[90, 92]  A sensitivity analysis 
asks how hidden biases of various magnitudes might alter conclusions, [92] in other words, how 
sensitive are the results are to unmeasured factors? [101, 102]  Models for sensitivity analysis 
can be expressed in terms of assignment probabilities: how large in magnitude would differences 
in the probability of receiving treatment depending on hidden biases need to be to alter the 
quantitative conclusions of a study? Alternatively, models for sensitivity analysis can be 
expressed in terms of unobserved covariates: how large in magnitude would confounding due to 
unobserved covariates need to be to alter the quantitative conclusions of a study?  
Mathematically, these two types of models are equivalent.[90]  
ii. Known Effects 
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 A sensitivity analysis shows how biases of different magnitudes might change 
conclusions, but it does not determine if biases are present, and their possible extent.[90]  An 
additional method to address hidden bias involves measuring an additional outcome for which 
there is no logical causal relationship with the studied treatment, or exposure.[90]  If a systematic 
difference in this outcome is detected between treated and untreated subjects, this cannot be an 
effect of the treatment and must be evidence of a hidden bias.  The use of multiple control groups 
in a case-control study is a related method. 
iii. Instrumental variables 
Instrumental variables, observable factors related to treatment choice but unrelated to 
characteristics of patients or to outcomes, can help adjust for unmeasured confounders.[101, 102]  
A major potential limitation of the instrumental approach is that it is often difficult to find a suitable 
instrument.   
iv.  Case-crossover studies 
Case-crossover and crossover-cohort studies can also help minimize inter-individual 
differences in indication for receiving antibacterials.[103, 104]  In this analysis, only data from 
patients experiencing adverse events are used.  A window of case exposure time is defined 
related to the adverse event occurrence, and exposure during this case-time is compared with 
exposure during either all control time (crossover-cohort studies) or exposure during a portion of 
the subjects’ control time (case crossover studies).  In sensitivity analysis, we can determine how 
much unmeasured confounding would be needed to change the odds ratio for serious adverse 
events for antibacterial drug-exposed vs. unexposed patients.[97] 
Utilizing these analytic methods with THIN data will support these research projects 
regarding antibacterial drug use as well as inform future THIN research projects and other studies 
using observational data where randomized clinical trials are not immediately feasible.   
 
c) Measurement error/misclassification 
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 Electronic medical record data tend to have rich longitudinal clinical information 
at the individual patient level.  Most pharmacoepidemiology techniques for utilizing observational 
data have come from studies of long-term drug use to treat chronic diseases and may not be as 
appropriate for studying more short-term drug exposures for acute conditions, for example acute 
infectious illnesses.  For acute conditions, even modest errors in measuring the onset or duration 
of acute conditions and/or exposures could bias the results.  We need to develop or adapt, and 
validate techniques developed using observational data to study chronic treatments and 
outcomes of chronic diseases to study acute conditions and/or exposures 
i. Misclassified outcome 
Hospitalization outcomes in electronic medical record data.   
Manually-entered outcomes may be particularly subject to error; for example hospitalizations, 
which are important markers of severe adverse events.  If hospitalization dates are incorrectly 
recorded outside of a specified exposure window that is overly-narrow, we may systematically 
miss important outcomes; using an unnecessarily long window risks introducing noise, thus errors 
in either direction can reduce our power to reveal true relationships between drugs and adverse 
events.   
Data regarding hospitalizations often are not directly linked to the outpatient record but 
instead need to be entered manually.  THIN hospitalization data are entered manually by patients’ 
general practitioners after they review patients’ hospital discharge summaries.  
There are four main areas of uncertainty to be addressed if electronic medical record 
hospitalization data are to be useful for drug safety surveillance.  First, when hospitalization 
codes indicate a patient was hospitalized, did the patient truly have an overnight hospitalization, 
or, what is the positive predictive value of the electronic medical record hospitalization codes for 
identifying a hospitalization?  Second, if the patient was indeed hospitalized, is the discharge 
diagnosis recorded the true primary discharge diagnosis from the hospitalization? Third, and 
important for studying acute exposures, what is the relationship between the recorded hospital 
admission date and the true hospital admission date?  If a hospitalization is recorded after receipt 
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of the discharge summary, it may be recorded with a later date than the true admission date. 
Even if the hospitalization date falls within the exposure window of interest, if the recorded date 
erroneously falls outside the window, the adverse hospitalization event might be missed.  Fourth, 
what is the sensitivity of the electronic medical record for detecting adverse event 
hospitalizations?  The first three of these areas of uncertainty will be addressed with the current 
projects within the U.K. electronic medical record The Health Improvement Network (THIN); the 
fourth is beyond the scope of presently-available resources.   
ii. Misclassified covariates/exposure 
Electronic medical record prescription data are generally considered to be highly valid, as 
data entry usually generates the prescription of interest, and prescriptions are usually linked to 
their corresponding diagnostic indications.[105, 106]  Prescriptions in THIN are generated with 
data entry this way, and linked to a diagnosis at the time of entry; studies have supported good 
concordance with other prescribing measures, for example, THIN prescribing rates for asthma 
medication were similar to UK asthma prescribing rates using other national measures.[105]  
However, there remain several routes of potential exposure misclassification.  First, medications 
not associated with a medical record entry may be missed, such as medications from emergency 
department visits, administered in the hospital, or administered over the telephone without written 
record.  Second, these data describe what was prescribed, but not necessarily what medication 
was obtained and/or ingested by the patient of interest; data on which prescriptions were filled are 
not available in THIN.  Previous studies have shown that approximately 2% of prescriptions 
remain unfilled, and approximately 70% of these are for new prescriptions.[107]  Medications may 
be prescribed but not obtained, obtained but not ingested as directed, or, alternatively, 
medications may be ingested by patients that are unrecorded in the medical record, for example, 
given by medical provider as samples but not recorded, obtained from family members or friends, 
or purchased over-the-counter or otherwise without a prescription.  Third, exposure status will 
depend on the definitions used for that study, for example, how encounters are included and/or 
grouped, and how exposures are otherwise defined for that particular study.  Medication 
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adherence rates are typically higher in patients with acute vs. chronic conditions,[108, 109] and, 
unlike for many U.S. patients,[110] payment for medications should not be a barrier in THIN as 
antibiotic prescriptions should be covered by the U.K.’s National Health Service.  In this study, we 
used a dichotomous exposure, exposed vs. unexposed. THIN does have medication dose and 
days supplied fields, but due to the extra potential for misclassification with these further variables 
described above, a dichotomous exposure was considered more useful for this study.  In addition, 
as the severe adverse events we were studying would mostly be considered Type B, or 
idiosyncratic adverse drug events, less likely dose related than the more common Type A 
adverse drug events,[111] the dose would not necessarily be as clinically relevant for this study.   
 
F. Preliminary Data 
 1. Adverse events related to antibacterial drug use in the GPRD: In a preliminary study, a 
50% sample of 2½ years of the GPRD was used to compare the incidence of adverse events for 
patients on short term (<28 days) vs. prolonged (>28 days) therapy with one of the seven oral 
antibacterial drugs: amoxicillin, amoxicillin-clavulanate, clarithromycin, azithromycin, ciprofloxacin, 
levofloxacin, and doxycycline.[112]  Serious adverse events resulting in hospitalization were 
identified including: nephrotoxicity, hepatotoxicity, anaphylaxis, infectious colitis, phototoxicity, 
seizures, and ventricular arrhythmias.  No analysis of unexposed patients was performed, and 
there was no adjustment for potential confounders.  Overall, 24% of patients were exposed to an 
antibacterial drugs of interest, including 542,817 person-years of observation.  Overall adverse 
event rates were highest for ciprofloxacin (24 events per 100,000 person days exposure) 
amoxicillin-clavulanate (15 events per 100,000 person days exposure) and amoxicillin (6 events 
per 100,000 person days exposure).  For most events, the incidence rate ratio, comparing >28 
vs. 0-28 person-days of antibacterial drug exposure was <1, showing limited evidence for 
cumulative dose-related adverse events from long-term exposure.  Limitations of this preliminary 
study include its relatively smaller sample size than this current study, no control group of patients 
not exposed to antibacterials, and no adjustment for potential confounders 
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 2. The Health Improvement Network (THIN): THIN is a large longitudinal observational 
database of anonymized computerized primary care medical records.  The GPRD was originally 
established by EPIC, London, U.K. in 1987 for research purposes; participating general 
practitioners received practice computers and Vision clinical practice management software in 
return for undertaking data quality training and submitting anonymized patient data.  Beginning in 
2002, a more formal collaboration of CDC EPIC with InPS, supplier of the Vision software, paved 
the way for the introduction of THIN.  THIN collects anonymised patient data records from general 
practices throughout the UK using the Vision software to create a medical research database.  
Within the UK, approximately 98% of the population is registered with general practitioner 
physician who is responsible for almost the entirety of the patient’s medical care.  THIN contains 
primary care records including demographics, provider information, medical diagnoses that are 
part of routine care or result from hospitalization, visits for acute conditions and diagnoses, 
consultations, hospital referrals, new and repeat prescriptions with indications for all new 
prescriptions (cross-referenced to medical events on the same date) and events leading to 
withdrawal of a drug or treatment, preventive care, hospital admissions, mortality and cause of 
death, lifestyle factors, and free text.[113]  The most current THIN data used in this study include 
information on 32.6 million person-years regarding 4.85 million patients from 326 practices.  
These data are completely de-identified; there is no way for investigators to link THIN records 
with any individual patient.  Diagnoses are recorded with Read diagnostic codes, using a 
comprehensive hierarchical nosologic system to group and define specific illnesses.  
Prescriptions are recorded using codes issued by the Prescription Pricing Authority (PPA) of the 
National Health Service in the UK.  Practitioners are trained in data entry and their data are 
reviewed on an ongoing basis for quality and completeness.[114, 115]  THIN helps GPs improve 
their data quality by offering training and analysis of the practice’s anonymised patient 
information, and reports back to practices on a regular basis.  Studies have confirmed very good 
validity of general practitioners’ documented diagnoses,[105] prescription information,[105] and 
capture of information from specialists.[116]  THIN also offers the option of obtaining additional 
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data from GPs if needed, while maintaining complete anonymization of data; this can be 
especially helpful for data validation.  All studies using THIN data must be approved by the local 
University of Pennsylvania THIN user committee, the local institution’s Institutional Review Board, 
and EPIC in the UK, to ensure scientific and ethical standards for THIN data utilization.  
 
G. Summary of background and relation to objectives of proposed study 
 Every individual in the U.S. is prescribed a short-term course of systemic antibacterial 
drugs once every three years to almost twice per year, on average, resulting from a visit to an 
ambulatory health care provider.[3, 4, 6, 37, 117, 118]  This extraordinarily high exposure to 
antibacterial medicines should command careful vigilance to the consequences.  Much U.S. 
antibacterial use is unnecessary, and contributes to rising antibacterial resistance.  Yet the factors 
that inform patient and provider expectations and decisions regarding antibacterial drug 
prescribing at the individual encounter level are influenced less by societal issues and more by 
prescriber and patient perceptions of patient-level attributes regarding individual benefit and 
risk.[119]  It is important to have a comprehensive understanding of the risk of adverse events 
related to this class of medication to which the U.S. public has virtually universal exposure.   
 Several recent trends that are likely to influence antibacterial drug use make it even more 
important to accurately assess risk.  As we face increasingly resistant organisms, and our 
antibacterial drug stewardship becomes ever more vital, providers are being urged to further 
decrease the rate of unnecessary antibacterial drug use.  However, an increasing prevalence of 
relatively frail and medically complex elderly members of the U.S. population works against our 
ability to use fewer antibacterial drugs.  Advances in personalized medicine and more complex 
decision modeling[120] require more precise information available regarding risk, adjusted for 
individual characteristics.   
 Many adverse events associated with antibacterial drug use have been documented in 
the past, those related to cardiac arrhythmia and CYP3A4 metabolism are of particular recent 
interest, however the causal relationship between antibacterial drug exposure and the adverse 
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event is not always evident, and risk models do not always address complex confounding issues, 
especially confounding by indication.   
 More information about individual patient outcomes of antibacterial drug use might help 
us learn how to better address antibacterial use and overuse at the individual level.  While large 
prospective randomized studies would be ideal to explore antibacterial drug outcomes, they are 
not immediately feasible for every research question.   
 THIN offers unique access to individual patients’ longitudinal demographic, clinical, 
pharmaceutical, and outcome data, and the opportunity for data validation.  Although these 
observational cohort data are more accessible than are the resources for performing a very large 
randomized clinical trial, great care needs to be taken to assure that the antibacterial drug -
exposed and -unexposed groups are as comparable as possible. Methods to control confounding, 
especially confounding by indication, and confounding by practice in observational studies can be 
used to enhance THIN studies regarding outcomes of medication use.     
 These studies expand on the preliminary study in that we use a subset of the entire THIN 
cohort with an office visit for acute nonspecific respiratory infection, and compare adverse event 
rates of antibacterial drug-exposed and antibacterial drug-unexposed patients.  By limiting the 
comparison to patients with visits for acute nonspecific respiratory infection, we promote 
comparability between exposed and unexposed patients in the cohort.  In addition, we explore a 
set of secondary adverse event endpoints of less serious events resulting in outpatient office 
visits.  We also comprehensively address confounding issues by utilizing different ways to adjust 
for practice-level confounding as well as patient-related covariates such as demographic 
variables, underlying health status and intensity of exposure to the medical care system.  The 
rarity of our outcome presents an additional analytic challenge.  To further assess our methods, 
and put our results in perspective, we also consider other outcomes, both benefits and adverse 
outcomes.   
With its wealth of longitudinal clinical information, THIN is the most logical database 
choice for this project, giving the best chance of teasing out antibacterial drug-related adverse 
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events from the confounding factors.  We also validate THIN hospitalization dates, which is 
pertinent for this study as well as for future studies of acute drug exposures using THIN data.  
This study provides the opportunity to learn about important antibacterial drug risks, as 
well as gain experience with methodologies that can be applied to future THIN studies to address 
issues inherent in using observational data.  As The Health Improvement Network (THIN) as well 
as other electronic medical record databases continue to grow in number and size, experience 






































































































































































































































































































Chapter 2. Specific Aims 
 The increasing availability of observational data from large electronic medical record 
databases provides opportunities to enhance our understanding regarding drug safety.  Most 
pharmacoepidemiology techniques for utilizing these data have come from studies of long-term 
drug use to treat chronic diseases and may not be as appropriate for studying more short-term 
drug exposures for acute conditions.  For example, there are limited data validating correct time 
windows for ascertaining acute medication exposures and the outcomes of cute conditions.  
 The first study will describe patterns of antibacterial drug use associated with outpatient 
visits for acute nonspecific respiratory tract infections in the THIN database.  The second study is 
a validation study addressing the accuracy of hospitalization dates in The Health Improvement 
Network (THIN), an electronic medical record database.  First, we will measure the positive 
predictive value of hospitalization codes in the database.  Next, for validated hospitalizations, we 
will explore the relationship between the recorded and true hospitalization dates.  Evidence either 
for or against the null hypothesis that the recorded dates are true dates, and resulting insight 
regarding a useful antibiotic exposure window will be essential for the subsequent studies 
assessing hospitalizations related to acute exposures.   
 Most adverse event reports regarding antibacterial drugs do not contain a control group 
of unexposed patients.  The third study in this thesis will use the knowledge acquired from the 
validation project regarding THIN hospitalization dates and appropriate drug exposure windows to 
study risks and benefits related to antibacterial drug use for acute nonspecific respiratory tract 
infections.  Antibacterial drugs are often prescribed for acute nonspecific respiratory infections, 
although they are unlikely to provide clinical benefit.  This scenario provides the opportunity to 
compare outcomes for exposed vs. for unexposed patients with similar conditions.  We will take 
advantage of THIN’s rich clinical data by applying several techniques to control for confounding 
by indication.  
 The goals of this dissertation are to address the unique methodological challenges of 
applying pharmacoepidemiologic techniques developed to study drug use for chronic diseases to 
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study more acute conditions, exposures, and outcomes, and specifically to validate 
hospitalization dates in THIN and to assess the relationship between acute antibacterial drug use 
and adverse events.   
 
Specific Aims: 
1. Describing antibacterial drug use for nonspecific acute respiratory illnesses in the U.K. 
 The objective of this study was to describe antibacterial drug use associated with a 
primary care visit for nonspecific acute respiratory illnesses in the U.K.’s The Health Improvement 
Network primary care database. Specific aims were to: 
Primary aim: 
1. Describe overall antibacterial drug use for acute nonspecific respiratory tract infections in 
the U.K. 
2. Describe broad spectrum antibacterial drug use for acute  nonspecific respiratory 
infections in the U.K. 
Hypothesis 1: Overall antibacterial drug prescribing for acute nonspecific respiratory infections is 
decreasing, similar to U.S. trends. 
Hypothesis 2: Broad spectrum antibacterial drug prescribing for acute nonspecific respiratory 
infections is rapidly increasing, also similar to U.S. trends. 
  
2. Assessing misclassification and validation of hospitalization dates and diagnoses in 
The Health Improvement Network (THIN) database 
 The objective of this study was to validate hospitalizations for community acquired 
pneumonia in the THIN database. Specific aims were to: 
Primary aims: 
1. Assess the positive predictive value (PPV) of a hospitalization for pneumonia identified 
using THIN hospitalization codes 
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2. Assess the relationship between THIN hospital admission date and true hospital 
admission date.   
Hypothesis: 100% of THIN hospitalizations are recorded as occurring within a 14-day window 
of the true hospitalization date.   
 
Hypothesis 1: : The PPV of a pneumonia hospitalization is 100%. 
Hypothesis 2: 100% of THIN hospitalizations are recorded as occurring within a 14-day 
window of the true hospitalization date 
 
3. Assessing methods for controlling bias and confounding while using observational 
clustered data to study rare outcomes. 
 The objective of this study was to compare various potential methods to control bias and 
confounding while using a primary care observational database to study rare acute outcomes. 
Primary aim: 
1. Compare methods for controlling bias and confounding caused by measured 
variables.  
Secondary aim: 
1. Compare methods to evaluate the impact of  unmeasured variables, including 
instrumental variable analysis and sensitivity analysis 
 
4. Potential Risks of Antibacterial Drug Use: Adverse Events Associated with Adult 
Antibacterial Treatment 
 The objective of this study was to compare the risk of a serious adverse event between 
patients prescribed antibacterial medications vs. the risk for those not prescribed antibacterials, 
conditional on a primary care visit for acute nonspecific respiratory tract infection.  Specific aims 
were: 
 Primary Aim: 
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1. To compare the risk of hospitalization with a severe adverse event between 
patients prescribed antibacterial medications vs. the risk for patients unexposed 
to antibacterials, conditional on a primary care visit for an acute nonspecific 
respiratory infection.   
 Hypothesis: 
Patients with visits for acute nonspecific respiratory infections with exposure to 
antibacterial medications have an increased risk of adverse event 
hospitalizations compared with antibacterial-unexposed patients with visits for 
acute nonspecific respiratory infections.   
 
5. Potential Benefits of Antibacterial Drug Use: Pneumonia hospitalization outcomes after 
acute nonspecific respiratory infection; assessing the influence of antibacterial treatment 
 The objective of this study was to compare the risk of a hospital admission for community 
acquired pneumonia between patients prescribed antibacterial medications vs. the risk for those 
not prescribed antibacterials, conditional on a primary care visit for acute nonspecific respiratory 
infection. 
 Primary aim: 
1. To compare the risk of hospital admission with community acquired 
pneumonia between patients prescribed antibacterial medications vs. the risk 
for patients unexposed to antibacterials, conditional on a primary care visit 
for an acute nonspecific respiratory infection.  
Hypothesis: 
Patients with visits for acute nonspecific respiratory infections with exposure to 
antibacterial medications have a decreased risk of pneumonia hospitalizations compared 




Chapter 3. Describing antibacterial drug use for nonspecific acute respiratory illnesses in 
the U.K. 
Meropol SB, Chen Z, Metlay JP. Reduced antibiotic prescribing for acute respiratory infections for 
adults and children. Br J Gen Pract. 2009;59(56):e321-328. DOI: 10.3399/bjgp09X472610 
 Resistance to antibacterial medications among community-acquired pathogens is a 
growing public health threat.[1-5]  Key drivers are the volume and type of antibacterials used in 
ambulatory settings.[6-8]  Antibacterials are often prescribed for acute nonspecific respiratory 
infections which they are unlikely to benefit..[9, 10]  Reducing such use can slow, or even reverse 
resistance rates.[11, 12]  U.S. and U.K campaigns have discouraged unnecessary antibacterial 
use.[2, 13-16]  Recent U.S. data have demonstrated decreased unnecessary adult and child use, 
but U.S. broad spectrum antibacterial use for adult and child acute nonspecific respiratory 
infections more than doubled during the 1990s, and have continued to rapidly increase through 
2006. [17-23]  U.K. studies have similarly shown decreased diagnoses of acute nonspecific 
respiratory tract infection and related and overall antibacterial use for all ages, [24-28], but they 
provided limited information regarding trends in adult and child antibacterial and broad-spectrum 
antibacterial use for this diagnosis.   
 The objective of this study was to assess recent U.K. trends in overall and broad 
spectrum antibacterial drug use for adult and child acute nonspecific respiratory tract infections.  
We hypothesized that overall use declined, that this decline varied by age and, like recent U.S. 
patterns, that there was a concomitant increase in broad spectrum drug utilization.   
 
Methods 
 Study Design: This retrospective cohort study utilized de-identified data from a large U.K. 
primary care electronic medical record database, The Health Improvement Network (THIN).[29]  
Data collection commenced in 1985 through the General Practice Research Database (GPRD); 
THIN, introduced in 2002, includes data from many original GPRD practices and continues to 
enroll additional practices with ongoing data collection.   
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THIN includes demographics, visits, diagnoses, and prescriptions.  Prescriptions are 
generated by data entry, and general practitioners are responsible for most prescribing, with 
virtually 100% capture of prescription data.  Data quality is reviewed on an ongoing basis.[29]  
Studies have confirmed good validity regarding documented diagnoses,[30, 31] prescriptions,[31] 
and specialists’ information.[32] 
 Study Population: The population of interest included permanently registered members of 
computerized THIN practices, utilizing THIN data as of September, 2007 describing 4.85 million 
patients from 326 practices, including >32 million person-years.  We used valid available data 
from January 1, 1990 or the date of practice computerization, if later, through December 31, 2004 
or the latest date of data collection for that practice.   
 THIN records birth year for all patients and birth month for children <15 years of age.  We 
defined adults as individuals >=18 years of age on the day of the acute nonspecific respiratory 
tract infection visit and children as being <18 years of age, according to THIN recorded 
birthdates.   
 We selected a cohort of visits from January 1, 1990 through December 31, 2004 using 
Read diagnostic codes for acute non-specific respiratory infections, chosen to represent 
conditions that are typically viral in origin and unlikely to respond to antibacterials (Table 1). We 
excluded conditions for which some guidelines recommend antibacterials, such as otitis media 
and sinusitis.  Because data from multiple visits within the same illness episode may be highly 
correlated, we grouped adjacent visits within a two-week window for our primary analysis; 
sensitivity analysis explored the impact of considering adjacent visits independently.  As results of 








Table 1. Acute Nonspecific Respiratory Tract Infection Diagnostic Codes 
THIN Read Code Description 
Other acute upper respiratory infections 
Acute upper respiratory tract infection 
Upper respiratory infection NOS 
Upper respiratory tract infection NOS 
Acute nasopharyngitis 
Acute pharyngitis 
Throat infection – pharyngitis 
Acute pharyngitis NOS 




 Outcome Classification:  The outcome of interest was receiving any antibacterial 
medication prescription within one day of an acute nonspecific respiratory tract infection visit.  
Drugs of interest included oral antibacterials typically used for respiratory infections.  We 
excluded topical, vaginal, ophthalmologic, otic, and parenteral antibacterials, and those typically 
used for tuberculosis, fungal and parasitic infections.  We classified amoxicillin/clavulanate, 
azithromycin, clarithromycin, fosfomycin, second- and third-generation cephalosporins and 
quinolones as broad spectrum, and all others as narrow-spectrum medications.[22]   
 Exposure Classification: The main exposure was visit year, considered individually for all 
analyses.   
 Covariates:  For children, age was stratified as 0-<5 and >=5 years of age.  For adults, 
age was stratified as 18-<65 and >=65 years.  These age categories are clinically relevant (i.e. 
pre-school vs. school-aged), are in line with those used by the U.S. National Center for Health 
Statistics,[33] and can facilitate comparisons with U.S. Medicare data for adults >=age 65.  Other 
covariates included sex, the number of comorbidities by the day of the ARI visit, and the number 
of different classes of prescribed medications and the number of visits within the year before the 
visit.[34-36]  As changes in drug use could vary by age, we also tested for an interaction between 
year and age category. 
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 Analysis: We first described trends in visit rates and antimicrobial prescribing rates for 
acute nonspecific respiratory tract infections over the study period using Cuzick’s nonparametric 
test for trend across ordered groups by individual visit year.  Person time was calculated using 
each patient’s THIN birthdate, practice enrollment date, date of transfer out of practice, and/or 
date of death, and each practice’s computerization and/or last data collection date, as 
appropriate.   
 Next, we used generalized linear models to model the probability of an antibacterial 
prescription, conditional on a visit for acute nonspecific respiratory tract infection.  To predict 
probabilities, we used a Poisson distribution and logarithm link function in the generalized linear 
models, with robust variance estimates [37].  Separate adult and pediatric models adjusted for 
clustering by patient and practice using Generalized Estimating Equations,[38, 39]. We modeled 
the probability that an antibacterial was prescribed, first using models adjusted only for year.  We 
report probabilities of antibacterial use for each year, and report trend across year using Cusik’s 
test.  We then modeled the probability of antibacterial prescribing using fully-adjusted models, 
with year as a linear term, including all covariates described above, to report adjusted trend 
across year, described as an incidence rate ratio (IRR) for each successive year.  We also 
explored the age-year interaction using the fully adjusted model including the interaction between 
age category and categorical year and tested whether interaction terms were significant using the 
deviance difference test.[40]  If interaction terms were statistically significant, we report IRRs for 
each successive year stratified by age category.   
 We performed a parallel set of analyses for broad spectrum antibacterial drugs, including 
trends in prescribing rates and the probability of antibiotic prescriptions conditional on a visit for 
acute nonspecific respiratory tract infection.   
 Analyses were performed using Stata version 9, StataCorp LP.  
 This study was granted exempt status by the University of Pennsylvania Institutional 
Review Board, and approval by the University of Pennsylvania THIN User Committee and the 





ARI visit rate 
 We identified 1,342,365 visits for acute nonspecific respiratory tract infection diagnoses in 
745,044 adults followed for 22,741,927 person-years and 1,117,596 visits for acute nonspecific 
respiratory tract infection diagnoses in 453,584 children followed for 5,831,438 person-years.  For 
adults, the visit rate during 1990 was 74.5 visits per 1000 person-years and by 2004 was 50.2 
visits per 1000 person-years (Figure 1).  For children, the visit rate during 1990 was 247.9 per 
1000 person-years and by 2004 was 154.5 per 1000 person-years (Figure 1).  Visit rates 
decreased over the study period for adults and children (both p for trend=0.001).   
 
Figure 1, Adult and Child Visit Rates for Acute Nonspecific Respiratory Tract Infections 









































Acute Nonspecific Respiratory Tract Infection antibacterial prescription rate 
 For adults, in 1990, the antibacterial prescription rate for acute nonspecific respiratory 
tract infection visits was 55.0 per 1000 person-years, and by 2004 it was 30.3 per 1000 person-
years (p=0.001 for trend) (Figure 2).  For children, in 1990, the antibacterial prescription rate was 


















Figure 2, Adult and Child Antibacterial Drug Prescribing Rates for Acute Nonspecific 











































Probability of antibacterial drug prescribing conditional on visit for acute nonspecific 
respiratory tract infection 
 For adults, during 1990, 71% of visits were associated with an antibacterial prescription, 
















































































 Using the fully-adjusted model for adults, adjusting for sex, age category, year, 
comorbidities, number of medications and number of visits, there was a significant decrease in 
the probability of antibacterial prescribing for each successive year, with an IRR of 0.979 (95% 
c.i. 0.979-0.980, p<0.001).   
 Using the fully-adjusted model for adults, and including the year-age category interaction, 
older adults were initially less likely to receive antibacterials ( p<0.001 comparing older and 
younger adults in every year) until 1998; when older and younger adults were equally likely to 
receive antibacterials (p=0.93 older vs. younger adults); after 1998, older adults were more likely 
to receive antibacterials (p<0.001 comparing older and younger adults in every year after 1998).  
Both age categories experienced significant declines in the probability of antibacterial prescribing 
over the study period; the IRR for year for ages 18-<65 years was 0.977 (95% c.i. 0.977-0.978) 
and for >=65 years was 0.988 (0.987-0.988).  The age-year interaction was significant (p<0.001) 
indicating that over time, antibacterial prescribing declined more steeply for younger than for older 






















 For children, during 1990, 46% of acute nonspecific respiratory tract infection visits were 
associated with antibacterial prescriptions, and by 2004, 31% of visits were associated with 
antibacterials (p=0.007 for trend) (Figure 3).   
 Using the fully-adjusted model for children, there was a significant decrease in the 
probability of antibacterial prescribing for each successive year, with an IRR of 0.959 (95% c.i. 
0.959-0.960, p<0.001).   
 Using the fully adjusted model for children, and including the year-age category 
interaction, older children were 30%-40% more likely than younger children to receive 
antibacterial prescriptions in every study year (p <0.001 comparing older vs. younger children in 
each study year).  Both age categories experienced significant declines in antibacterial drug 
prescribing over the study period; the IRR for year for ages 0-<5 years was 0.959 (95% c.i. 0.958-
0.959) and for >=5 years was 0.962 (0.961-0.963) indicating the rate of decline was similar in 
both age groups.  While the age-year interaction term was statistically significant, the effect of 
year, and thus its public health relevance, was essentially the same in both age groups.   
Broad spectrum antibacterial prescribing rate for acute nonspecific respiratory tract 
infections 
 For adults, the broad spectrum antibacterial drug prescription rate during 1990 was 3.8 
prescriptions per 1000 person-years, and by 2004, was 2.9 prescriptions per 1000 person-years 
(p=0.005 for trend) (Figure 4).  For children, the broad spectrum antibacterial prescription rate 
during 1990 was 5.2 prescriptions per 1000 person-years, and by 2004 was 2.2 prescriptions per 





















































Probability of broad spectrum antibacterial prescribing conditional on visit for acute 
nonspecific respiratory tract infection 
 For adults, during 1990, 4.4% of visits for acute nonspecific respiratory tract infection 
were associated with broad spectrum antibacterials, this portion peaked at 7.8% by 1996 and 
then decreased to 5.6% by 2004 (p=0.16 for linear trend over study period) (Figure 5).  
 Using the fully adjusted model for adults, there was a small decline in the probability of 
broad spectrum antibacterial prescribing for each successive year, with an IRR of 0.96 (95% c.i. 
0.96-0.97, p<0.001).  
 For children, during 1990, 2.0% of visits were associated with broad spectrum 
antibacterial prescriptions, (Figure 5); this percentage peaked at 2.8% in 1995 and then 
decreased to 1.4% by 2004 (p=0.01 for trend).   
 Using the fully adjusted model for children, there was a small decline in the probability of 
broad spectrum antibacterial prescribing for each successive year, with an IRR of 0.95 (95% c.i. 
















































































Summary of main findings 
 Our study demonstrated that antibacterial drug prescribing for acute nonspecific 
respiratory tract infections decreased in the U.K. for adults and children from 1990-2004.  The 
decline in antibacterial use was faster for both older and younger children than for adults, 
although use in younger adult declined faster than for older adults.  Possible reasons for these 
differences include the influence of the pneumococcal conjugate vaccine on the perceived risk of 
child bacterial illness,[41-43] and on parents’ health through herd effects,[43, 44] a potentially 
initially wider pool of unneeded antibacterial use in younger individuals, and a possible differential 
effect of public educational efforts regarding antibacterial use for young adults, influencing their 
own use and that of their children.  The relative contributions of each of these or other factors to 





























 Despite decreasing antibacterial use for acute nonspecific respiratory tract infections, we 
did not observe a concomitant increase in broad spectrum antibacterial prescribing.  In fact, we 
found encouraging evidence for low and recently decreasing broad spectrum antibacterial use 
associated with this diagnosis for U.K. adults and children.  
Strengths and limitations of the study 
 Strengths of this study relate to the use of THIN data. Advantages of THIN vs. claims 
data are THIN’s direct links to longitudinal clinical data and that THIN does not depend on billing 
or insurance status.  Advantages of THIN vs. survey data are that THIN is a 100% sample of 
practice patients and that the medical record itself is the data collection form. 
 Potential limitations of this study include that some antibacterials may have been missed, 
for example, telephoned prescriptions without an associated visit.  Second, we have no data 
regarding whether prescribed drugs were ingested.  Third, visit grouping may have misclassified 
some unexposed visits as exposed and falsely inflated our antibacterial use estimates, however 
our sensitivity analysis considering ungrouped visits showed similar results.  Next, our 
observational study does not allow us to address which policies or clinical trends caused the 
observed changes.  Finally, our study did not address outcomes of antibacterial use and could 
not directly assess prescriptions’ appropriateness.   
Comparisons with existing literature 
 The population rates of visits for acute nonspecific respiratory tract infections we 
observed are similar to those previously reported for U.S.adults and children.[19, 21, 45]   
 The trends in overall antibacterial use we observed are comparable to U.S. trends.  Using 
National Ambulatory Medical Care Survey (NAMCS) data, Roumie et al, reported that 
antibacterial prescribing for adult acute nonspecific respiratory respiratory tract infections declined 
from 60% in 1995-1997 to 43% in 1999-2000.[19] Steinman et al. also used NAMCS data to 
report decreased antibacterial prescribing for adult acute nonspecific respiratory tract infections 
from 56% in 1991 to 43% in 1999.[20]  Similarly, Steinman et.al. reported declining antibacterial 
use for child acute nonspecific respiratory tract infections, from 41% in 1991 to 21% in 1999.[20]  
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Grijalva and colleagues used NAMCS data to show that U.S. use of antibacterials to treat adult 
and child acute nonspecific respiratory tract infections continued to decrease during the early 
2000s, and that broad spectrum antibacterial drug use for this diagnosis continued to increase in 
adults and children.[23]   
Our demonstrated decline in U.K. antibacterial drug prescribing for adult acute 
nonspecific respiratory tract infections, from 71% in 1990 to 59% in 2004, is similar to these U.S. 
reports.  In our cohort, child antibacterial use for acute nonspecific respiratory tract infections 
decreased from 46% in 1990 to 31% in 2004.   
 Our low and recently decreasing use of broad spectrum antibacterials for adults and 
children in the U.K. are quite different from U.S. trends, evidence that recent U.K. campaigns to 
enhance judicious antibacterial use may be paying off.[14-16]   
Implications for further research or clinical practice 
 Reasons for the large discrepancies in trends in broad spectrum antibacterial use 
between the U.K. and U.S. are unknown, but could relate, at least in part, to differences in health 
care delivery.  U.S. health care is managed by a mix of privately- and publicly-financed 
mechanisms, emphasizing a competitive business model.  Prescribing is influenced by separate 
formularies for each of thousands of individual health plans, and pharmaceutical industry 
promotion to physicians and the public.  The U.S. CDC’s “Get Smart” campaign targeted parents 
with the message that using antibacterials for acute nonspecific respiratory tract infections put 
their children at greater risk of a future resistant infection.  U.K. health care is managed by a 
government-financed national system which sets explicit priorities to enhance public health 
through specific incentives.  Medications are managed through national formularies with 
performance monitoring of antibacterial drug prescribing.  The U.K.’s campaign, “Antibiotics: 
Don’t Wear Me Out,” targeted the general public with the message that controlling antibacterial 
drug resistance benefits everyone.   
 Successful strategies to further reduce antibacterial drug overuse are likely to have 
strong central leadership, with explicit priorities emphasizing societal benefit, and be supported by 
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robust financial and regulatory incentives.  Professional and public education, while necessary, 
are usually not sufficient to change behavior; successful strategies for improving antibacterial use 
are usually multifaceted.  More data are needed regarding outcomes of strategies to reduce 























































































































Chapter 4. Methods I: Misclassification and validation of pneumonia hospitalizations in a 
primary care electronic medical record database 
 To take advantage of the increasingly available observational electronic medical record 
data to support post-marketing drug effectiveness and drug safety surveillance, it is important to 
validate the outcomes that will be used in such studies. In particular, hospitalization diagnoses 
are important markers of adverse event severity. To be able to identify adverse events within a 
specified exposure time window, it is also important to able to ascertain the precision of 
hospitalization dates. Validation of The Health Improvement Network (THIN) adverse events and 
hospitalization dates in this study can thus inform many important future observational THIN 
studies of the outcomes of medication use, for antibacterial drugs as well as for other types of 
medications. The hypothesis is that hospitalization diagnoses and dates will be valid within 
clinically important limits.  
After U.S. FDA approval, drugs are used for many more patients, for a wider variety of 
indications, and for a more heterogeneous patient population than in pre-approval trials. The 
importance of post-marketing drug safely surveillance is increasingly recognized. Observational 
studies can take advantage of accumulating electronic medical record data to enhance post-
marketing outcome studies. Electronic data come in two basic flavors, with some overlap. 
Because they are used for billing, administrative data tend to have information on drugs 
dispensed, and relatively precise hospital admission dates and discharge diagnoses. Electronic 
medical records on the other hand tend to have rich longitudinal clinical data at the individual 
patient level, however inpatient data regarding hospitalizations often are not directly linked to the 
outpatient record and instead need to be entered manually.  
The projects in this dissertation used data from The Health Improvement Network (THIN). 
THIN is an electronic medical record database containing longitudinal primary care data from 
patients in the United Kingdom including demographics, visits, diagnoses, prescription 
medications, laboratory testing, mortality, cause of death, and hospital admissions.  However, as 
indicated above, the software used for THIN was developed as an ambulatory medical record 
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system; inpatient and ambulatory medical records are not yet integrated in the U.K., and 
hospitalization data are entered manually by patients’ general practitioners after they review 
patients’ hospital discharge summaries.  
There are three main areas of uncertainties to be addressed if THIN hospitalization data 
are to be useful for drug outcome research. First, when THIN hospital admission codes indicate a 
patient was hospitalized, did the patient truly have an admission to a hospital, or what is the 
positive predictive value of the THIN hospitalization coded for identifying a hospitalization? 
Second, if the patient was indeed hospitalized, is the primary discharge diagnosis recorded in 
THIN the true primary discharge diagnosis from the hospitalization? Third, what is the relationship 
between the recorded hospital admission date and the true hospital admission date?  If the 
hospitalization is recorded after receipt of the discharge summary, it may be recorded with a later 
date than the true admission date. Even if the true hospitalization date falls within the exposure 
window of interest, if the recorded date erroneously falls outside the exposure window of interest, 
the hospitalization event might be missed.  
The objective of this study is to validate hospitalizations in the THIN database. The 
specific aims were to:  
1. Assess the positive predictive value (PPV) of a hospital admission for community 
acquired pneumonia identified using THIN hospitalization codes. Our hypothesis was 
that the PPV of a pneumonia hospitalization is 100%. 
2. Assess the relationship between THIN hospital admission date and true hospital 
admission date.  Our hypothesis was that 100% of THIN hospitalizations will be 
recorded as occurring within a 14-day window of the true hospitalization date.   
 
Methods 
 This study design was a retrospective cohort study.  Adults with ambulatory primary care 
visits for acute nonspecific respiratory tract infections in the THIN database from June, 1985 
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through August, 2006 were identified using Read diagnostic codes. (Table 1)  These visits are 
hereafter referred to as our cohort of ARI visits.  
  Study Outcome 
Adults with overnight hospital admissions for community acquired pneumonia within 30 
days of an ambulatory encounter for acute respiratory tract infection in the THIN database were 
identified using Read diagnostic codes for pneumonia and THIN hospitalization codes.  Of these 
adults with hospital admissions for pneumonia, sixty were randomly selected for validation.  
Validation of 60 hospital admissions for pneumonia was feasible given available resources, and 
would give us the power to test both of our hypotheses within clinically significant limits (see 
below).   
We focused on hospitalizations for community acquired pneumonia for this aim for 
several reasons.  First, hospital admission for community acquired pneumonia is a relatively 
common event following ARI, giving us a robust sample of reasonably similar outcomes to be 
able to correctly estimate the measurement error.  Additionally, we had a separate clinical 
research interest in whether risk of hospitalization for community acquired pneumonia is elevated 
after an ARI visit, and whether antibiotic treatment reduces this risk.  We pursued this related 
question in Chapter 7 of this dissertation.   
Gold Standard Outcome 
Each subject’s de-identified THIN patient and practice identification codes, and a date 
window including 90 days before and following the ARI visit were forwarded to the subject’s 
general practitioner (GP) through EPIC Database Research Company.  The GPs identified 
records from their patients’ charts that are supplementary to the electronic THIN data. For the 
specified patients, GPs returned de-identified photocopies of all hospitalization discharge 
summaries, consultants’ letters, and any additional material related to any overnight 
hospitalizations within the specified date window.   
 EPIC checked the data to ensure complete anonymization prior to forwarding them to 
investigators. We then examined patient records for the following information: 
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a)  Did the subject have an overnight hospitalization within the window?  
b)  What was the hospital admission date?  
c)  What were the primary and additional discharge diagnoses? 
This study was approved by the University of Pennsylvania Institutional Review Board and the 
Medical Research Ethics Committee, National Research Ethics Service of the U.K. National 
Health Service. 
Analysis 
For our first aim, the PPV of a THIN hospital admission for community acquired 
pneumonia during the 30 days following the ARI visit was calculated as the number of patients 
with GP-validated hospital admissions divided by the total number of THIN hospitalizations, with 
exact binomial confidence intervals.  The PPV of the specific pneumonia THIN adverse event 
hospitalization diagnosis was calculated as the number of patients with confirmed GP-validated 
pneumonia diagnoses divided by the total number of confirmed hospitalizations, with exact 95% 
binomial confidence intervals.  Two-sided two-sample t-tests were used to compare means of 
characteristics between admitted and nonadmitted patients, assuming unequal variances 
between groups. 
For our second aim, analysis included data only for those patients with confirmed 
overnight hospital admissions. The mean and median absolute difference in dates between the 
THIN and the actual hospital admission date were defined.  Stata, versions 9.2 and 10.0, were 
used for all analyses (StataCorp College Station TX, 29-Jan 2007 and 1 Oct 2009).  
Power 
PPV of a hospital admission for community acquired pneumonia   
 We included 60 patients in this validation study.  Lewis and colleagues, using the General 
Practice Research Database, a precursor to THIN, found the PPV for identifying inflammatory 
bowel disease hospitalizations was only near 50%.[1]  With a 2-sided α=0.05, and N=60,  
examples of confidence intervals predicted for a widely representative range of PPVs are shown 




Table 2. Positive Predictive Value (PPV) of a THIN-coded Hospital Admission for 
Community Acquired Pneumonia after a Ambulatory THIN ARI Visit  
PPV 95% confidence interval
 N=30 N=60 
0.50 0.31-0.69 0.37-0.63 
0.75 0.57-0.90 0.62-0.85 
0.80 0.61-0.92 0.68-0.89 
0.85 0.69-0.96 0.73-0.93 
0.90 0.73-0.98 0.79-0.96 
0.95 0.78-0.99 0.86-0.99 
 
 The better the PPV (closer to 100%) the narrower the 95% confidence limits. As shown 
above, with 60 patients, even with a low PPV, we should have the power to estimate the PPV of a 
THIN pneumonia hospitalization within clinically significant limits.   
 
Difference, THIN hospitalization date vs. true hospitalization date 
 Our power to detect a difference in days between the THIN hospitalization date and the 
true hospitalization date is most dependent on the PPV and the standard deviation of the 
distribution of differences.  Lewis and colleagues compared the first mention of inflammatory 
bowel disease diagnoses with the diagnosis dates confirmed by GP survey; these date 
differences showed a highly skewed distribution with an estimated standard deviation 
approximately twice the mean days difference.[1]  For our patients with documented 
hospitalizations within the date window, the differences between the true and documented 
hospitalization dates are constrained by our date window 30 days following the ARI visit and thus 
are unlikely to be as skewed.  McPhee and colleagues validated mammogram and PAP smear 
recall dates and analyzed mean date differences.[2]  They found standard deviations (SDs) equal 
to the mean days difference.   
 Using a 2-sided α=0.05, with N=60, with our estimated standard deviation equal to the 
mean days difference, even with a PPV as low as 50%, we would have 99% power to detect an 
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absolute difference as small as 1-2 days.  As differences smaller than this would not be clinically 
significant, and time of hospitalization is not recorded in THIN, the analysis does not need to be 
sensitive down to the level of hours, or fraction of a day.  With a PPV of 75%, even if our standard 
deviation is twice the mean days difference, we would still have 92% power to detect a clinically 
important difference in days.  In Table 3, we present power estimates based on a targeted 
collection of 60 hospitalization records and a conservative collection of 30 hospitalization records, 
based on PPV for hospitalization, missing records or physician non-participation. 
 
Table 3. Power, Difference, THIN Hospitalization Date vs. True Hospitalization Date,  
α, 2-sided = 0.05,  
Days SD (days) PPV Power 
   N=30 N=60 
30 60 0.50 0.78 0.49 
30 30 0.50 0.99 0.97 
30 60 0.75 0.92 0.65 
30 30 0.75 0.99 0.99 
14 28 0.50 0.78 0.49 
14 28 0.75 0.92 0.65 
14 14 0.50 0.99 0.97 
7 14 0.50 0.78 0.49 
7 14 0.75 0.92 0.65 
7 7 0.50 0.99 0.97 
2 4 0.50 0.78 0.49 
2 4 0.75 0.92 0.65 





Predictive value of a THIN pneumonia hospitalization 
 Out of 60 patients with THIN pneumonia hospitalizations randomly selected and sent to 
EPIC for validation, 59 chart records were received from GPs (one GP did not respond to the 
inquiry).  Fifty two of these 59 patients were admitted to the hospital for an overnight stay within 
the 90-day window on each side of the ARI index visit date, giving a PPV of a THIN hospital 
admission of 88% (95% confidence interval 77% to 95%).  There was no difference in gender or 
age between the admitted vs. the unadmitted patients.  Twenty-three of 53 (43%) admitted 
patients and 3 of 7 (43%) unadmitted patients were male, Fisher’s exact test p=0.99.  The mean 
age of admitted patients was 52 years vs. 44 years for unadmitted patients, (p=0.33). One of 
these admissions did not have a discharge diagnosis of pneumonia according to the GPs chart 
records, giving a PPV for THIN pneumonia admission of 51/59 or 86% (95% c.i. 75% to 94%);.  
All of these admissions had pneumonia as the primary admission diagnosis.   
Difference between THIN hospitalization date and true hospital admission date 
 Of the 52 patients with valid THIN hospitalizations, 50 were actually admitted within 14 
days of the date recorded in THIN, with a range of -2 to +18 days. The absolute median 
difference between the THIN and validated admission dates was 1 day and the absolute mean 
difference was 3.1 days.   
In 16 of the 52 admitted patients, the THIN admission date was the discharge date listed 
on the GP hospital discharge notes.   
 
Discussion 
 Electronic medical records are a potentially enormous and rich source of data to 
examine, evaluate, and compare clinical outcomes.  Such large datasets can provide impressive 
results, however, size is of little value here if the data are of poor quality, and proceeding to 
analysis without validating important study parameters can corrupt the value of any results and 
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lead us to erroneous conclusions.  To take advantage of the increasingly available observational 
electronic medical record data to support post-marketing drug safety surveillance, it is important 
to validate the outcomes that will be used in such studies.[1, 3]  Hospitalization diagnoses are 
particularly important  markers of adverse event severity. To be able to identify acute events 
within a specified time window related to acute exposure, it is also important to able to ascertain 
the precision and accuracy of hospitalization dates.  This study had the power to validate THIN 
hospitalization dates within clinically important limits.   
Our PPV for THIN pneumonia hospitalization was as good or better than the PPV for 
acute care date estimation methods described in other studies.[1, 2, 4-7]  There were no obvious 
differences between the patient admissions that were validated and those that were not.  Our 
finding that 16 of the 52 admitted patients had the true hospital discharge date as the recorded 
THIN admission date implies that the accuracy of admission dates might be better for conditions 
that are associated with shorter vs. longer hospitalizations,.   
Virtually all (50/52 or 96.1%) of the recorded hospital admission dates were accurate 
within a 14-day window, providing support for our ability to identify adverse events resulting in 
hospitalizations related to acute drug exposures within THIN.   
 
Limitations 
 Bias: Limitations of this study include that we were limited by the validity of our presumed 
gold standard data from the GP charts.  The GPs were highly unlikely to find discharge 
summaries when a hospitalization did not actually take place, however, if the charts were missing 
discharge summaries from true hospitalizations, or if the GPs were unable to find them, then we 
may have misclassified some hospitalization diagnoses as false positives.  This information bias 
would tend to bias us away from the null hypothesis of 100% specificity.  This project is 
strengthened by the fact that THIN GPs are not just recruited for this study, but have a 
longitudinal relationship with EPIC Database Research Company.  Responding to research 
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queries is part of this relationship and they are financially compensated for their time and effort.  
EPIC thus has a track record of successful validation efforts similar to this study.[1, 8-10]   
 Generalizability: PPV and date differences may vary with patient age.  PPV and date 
differences may vary with diagnosis type; one potential source of this variation is the association 
of discharge date with THIN recorded admission date found in our study.  We had limited power 
to detect differences in PPV and date differences between hospitalization diagnoses included in 
this study, and did not address outcomes in addition to the included pneumonia hospitalization 
diagnoses in adults.  The validity of other outcomes, for example, death, was not addressed, nor 
were adverse events for children; our results are not necessarily generalizable to patients with 
different ages and different hospitalization diagnoses than included in this study.  We had more 
power to validate the PPV of any hospitalization than we did to validate diagnosis-specific 
hospitalization. The validity of medication exposure was not addressed.  The validity of THIN for 
identifying prescriptions is usually considered good, as the electronic medical record entry 
actually generates the patient’s prescription. There are data from early adoption of the computer 
system that support this validity. [9, 10]  
 Pharmacoepidemiologic studies using electronic medical record data regarding outcomes 
related to acute outpatient exposures depend on the ability to accurately and precisely identify the 
timing of valid outcomes.  THIN hospitalization codes performed well in identifying the timing of 
hospitalization events of interest. This study supports observational THIN studies regarding 
additional medication use outcomes, especially outcomes related to acute conditions and acute 
exposures to antibiotics as well as other medications.  Future studies should also pursue 
validating additional THIN outcomes, including those for children, further increasing the 
generalizability of our findings.   
 It is likely that electronic medical records will become increasing complex, potentially 
integrating patients’ ambulatory and inpatient data.  While this may improve the precision of 
admission diagnoses and dates, it could also introduce additional misclassification.  We will need 
Chapter 4  
51 
to continue to consider the precision of these clinical measures as we look forward to using these 





























Chapter 5. Methods II: Using observational clustered data to study rare outcomes, 
controlling bias and confounding 
Drug benefits are established in pre-marketing clinical trials.  These randomized clinical 
trials are designed to be conservative in demonstrating drug efficacy and liberal in measuring 
drug safety;they assess whether the drug produces benefit when users are perfectly compliant 
under otherwise ideal circumstances, and are typically evaluated using intention to treat (ITT) 
analyses.[1]  However this type of trial, may not be the best way to study risks under conditions of 
less-than-complete adherence in real-world practice settings where it’s not always straightforward 
to determine who is taking the drug in question.  In addition, small pre-marketing clinical trials are 
usually too small to evaluate even moderately common drug risks.[2, 3]  Large prospective 
randomized trials are not feasible for many research questions regarding moderate to small drug 
risks.  Most warnings of drug-related adverse event risks come from case reports, which, usually 
lacking an exposed denominator, and subject to under- and biased reporting, do not establish the 
true relative risk of adverse event risks related to drug exposure vs. non-exposure.[3]  Studies of 
exposures and outcomes using large administrative datasets without clinical data often do not 
address complex confounding issues, especially confounding by indication.[4]  For these reasons, 
studies utilizing large databases are often better-suited to help us understand drugs’ 
effectiveness and risks in the real-world practice setting.   
The growing availability of electronic medical records can provide databases containing 
large scale observational data.  The U.K.’s The Health Improvement Network (THIN) electronic 
medical record database offers access to individual patients’ longitudinal demographic, clinical, 
pharmaceutical, and outcome data.  These data are often more accessible than are the resources 
for performing very large randomized clinical trials, however if observational data are used to 
assess drug use outcomes, great care needs to be taken to assure that the drug -exposed and -
unexposed groups are as comparable as possible.[5]. 
We used a subset of the entire THIN cohort with an office visit for acute nonspecific 
respiratory infection (ARI), and compared adverse event rates of antibacterial drug-exposed vs. 
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antibacterial-unexposed patients.  By limiting the comparison to patients with ARI visits, we 
promoted comparability between exposed and unexposed patients in this cohort of otherwise 
similar patients.   
We sought an unbiased estimate for the association between antibacterial drug exposure 
for ARIs and our adverse event outcome.  Ideally, we would want to know, for the same patient 
with the same ARI visit, what is the relative risk of an adverse event if he/she receives a 
prescription for antibiotics at that ARI visit vs. if he/she doesn’t receive antibacterial drugs at that 
visit, or the ‘counterfactual’ estimate.[6]  Of course, there is no way to compare outcomes of 
antibacterial drug treatment vs. non-treatment for the same patient at the same visit.  A 
randomized clinical trial is the best way to approximate this counterfactual approach; successful 
randomization would ensure that exposures are balanced in terms of covariates at all levels.  As 
discussed above, randomized trials to explore the risks of potential rare events are not always 
feasible for every clinical question.  Using observational data, we aimed to estimate this 
counterfactual effect by obtaining the relative risk (or odds ratio or risk difference) of similar 
patients exposed vs. unexposed to antibacterial drugs.  To the extent that antibacterial 
prescribing was random among patients with ARI visits, and that all exposed and unexposed 
patients were otherwise at equal risk of an adverse event outcome, this estimate would provide 
an unbiased estimate of this counterfactual effect.   
However, our research problem presented three major challenges to obtaining this 
unbiased estimate of adverse event risks related to antibacterial drug use.  First, preliminary data 
showed that there was likely to be significant clustering by practice; exposure, outcomes, and 
covariates within practices will likely be much more similar than exposure, outcomes and 
covariates across (or between) practices.  As a result, an additional subject within a cluster adds 
less information than would an additional subject from a different cluster.  This effect on the 
variance, and resultant loss of power by the use of cluster sampling instead of simple random 
sampling is termed the design effect, and needed to be accounted for in the analysis.   
Second, antibacterial drug prescribing and baseline adverse event risk may both vary 
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widely between (across) practices, and this may result in a large degree of confounding by 
practice. Some practices may be more likely than others to prescribe antibacterials as they might 
have sicker or more demanding patients and/or physicians with higher tendency to use 
antibacterials, thus there may be different ratios of untreated vs. treated patient visits between 
practices.  Preliminary data showed that antibacterial drug exposure is indeed highly variable and 
highly related to practice.  Even within practice, treatment allocation may not be random but 
instead may be associated with many measured and unmeasured practice- and patient-level 
covariates. Practices may also vary in their patients’ baseline risk of adverse events; some 
practices may be more likely than others to experience severe adverse events due to observed 
and unobserved factors; for example, they may include more medically fragile patients.  Because 
of this potentially intense clustering and confounding by practice, involving both exposure and 
outcome, we needed to stratify our analysis by practice.  We sought the counterfactual effect of 
antibacterial drug exposure, specifically the relative risk of adverse event for a patient in a 
particular practice at a particular time exposed to antibacterials vs. that same patient in that same 
practice at that same time unexposed to antibacterials.  To minimize, as much as possible, the 
confounding by practice, our analysis needed to decompose overall antibiotic effects into the 
between- practice effects and the within-practice effects, because we were really interested in 
only these within-practice estimates of antibacterial drug risks.   
Our third major analytic challenge was that our outcome was exceedingly rare.  As we 
stratified on practice to consider these within-practice estimates, there woud be many practices 
expected to have zero outcomes.  In this situation, conventional methods of regression 
conditional on practice may not have been successful because of sparse data; we would lose all 
information from the practices with zero outcomes.  These zero-event practice sites added to the 
denominator of total exposure to antibacterial drugs.  There is reason to believe that adverse 
events would not be distributed randomly across practices, but instead that practices with zero 
outcomes may be different, in both measured and unmeasured ways, than practices with adverse 
event outcomes.  To maximize the knowledge we could gain from this study, we wanted our 
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analytic methods to allow us to make use of the information from practices with zero outcomes.  
We explored this problem using methods to adjust for confounding with different types of 
multivariable regression techniques.  These different multivariable methods utilized different 
assumptions, and may provide different, complementary, estimates, giving us a multifaceted 
picture of the relationship between exposure and outcome. .We needed to consider analytic 
methods suitable for trials of very rare outcomes; in some ways, this problem was similar to 
performing meta-analyses of studies of rare events.[7]  
The objective of this study was to compare various potential methods to control bias and 
confounding while using a primary care observational database to study rare acute outcomes. 
The primary aim was to compare methods for controlling bias and confounding caused by 
measured variables.  Our secondary aim was to compare methods to evaluate the impact of 
unmeasured variables, including instrumental variable analysis.  We hypothesized that standard 
methods for controlling bias and confounding by measured and unmeasured variables can be 
adapted for observational studies of clustered rare outcomes.   
Methods 
A. Description of the cohort 
 The data source for this retrospective cohort study was the September 2007 dataset from 
The Health Improvement Network (THIN).  A cohort of adult THIN primary care visits for 
nonspecific ARIs between January 1, 1985 and December 31, 2006 was selected from for THIN 
continuously-enrolled valid patients >18 years of age in THIN practices with valid data using the 
Read diagnostic codes for nonspecific respiratory infections listed in Chapter 3, Table 1.  Codes 
for respiratory infections were excluded if some guidelines recommend antibacterial treatment, 
such as streptococcal pharyngitis, otitis media and sinusitis.  Because data from multiple visits 
within the same ARI episode may tend to be highly correlated, visits were grouped if they 
occurred within a two-week period.  The outcome of interest for this study was severe adverse 
event, defined as hospitalization within 14 days following the index ARI visit with, cardiac 
arrhythmia, diarrhea, hepatic toxicity, hypersensitivity, photo-toxicity, renal toxicity, or seizure.  
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Exposure of interest was antibiotic prescription within one day of the index ARI visit; antibacterial 
drugs of interest included oral antibacterials typically used for respiratory infections.  We excluded 
topical, vaginal, ophthalmologic, otic, and parenteral antibacterials, and those typically used for 
tuberculosis, fungal and parasitic infections.  Covariates included patient age at time of visit, sex, 
visit year, Townsend score (a measure of neighborhood material deprivation), neighborhood 
racial mix, and patient comorbidity history, with comorbiditites grouped into the categories shown 
in Table 4 (Lewis, J.D., unpublished data).  Considering what clinical data might be relevant from 
a clinical aspect to help predict indication for antibacterial treatment of ARIs, we also included 
alternative summary measures of the intensity of medical care use, including the number of THIN 
recorded comorbidities,[8] and the number of different classes of medications[8, 9] and number of 
visits within the year prior to the index ARI visit.   
Table 4. Comorbidity Categories 
Comorbidity Categories 
Congestive heart failure Malignancy 
Lung disease Metastatic malignancy 
Rheumatologic disease Mild liver disease 
Cerebrovascular disease Moderate/severe liver disease 
Dementia Myocardial infarction 
Diabetes Peptic ulcer disease 
Weakness Peripheral vascular disease 
HIV Kidney disease 
 
B. Methods to model conditional rare outcomes 
We compared several different multivariable methods to model hospitalization within 14 days of 
the ARI visit for any severe adverse event, Table 5.  As described above, we are really interested 
in the counterfactual difference in risk of an extremely rare adverse event for an ARI patient in a 
particular practice exposed to an antibacterial drug vs. the risk for that same patient visiting the 
same practice for that same ARI at the same time, not exposed to an antibacterial.  To estimate 
the counterfactual within-practice outcome of interest, we explored several ways to decompose 
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within- vs. among-practice effects of antibacterial ldrug exposure, thus minimizing confounding by 
practice, in the setting of our extraordinarily rare outcomes and extreme imbalance of exposure 
and, potentially, outcomes across groups.  We also sought methods that could minimize the bias 
in the estimates for our very rare outcome by using data from practices with no adverse events 
1. Marginal Models (GEE method): We first considered implementing 
Generalized Estimating Equations (GEE), using Stata’s xtgee command.  GEE, a marginal model, 
can be used to adjust for clustering[10] and is typically not difficult to implement with a relatively 
large number of cluster groups (such as the number of patients and practices in this study).  GEE 
could potentially help us decompose the within- and between-practice effects to focus on the 
within-practice association between antibacterial drugs and adverse events, our contrast of 
interest.  However there are several reasons why GEE might not be an ideal method for this study.  
First, using GEE requires us to specify a correlation structure, although GEE is relatively robust to 
misspecification in this regard.  Second, it may be difficult to address multiple levels of clustering in 
GEE.  Third, GEE derives population-averaged outcomes. With normally-distributed outcomes and 
a linear model, the marginal effects derived from GEE, or the average differences for subject strata 
defined for different covariate values, can be expected to be the same as the subject-specific 
effects, or expected difference for individual subjects with different covariate values. However, this 
may not hold true for dichotomous outcome measures where the link function between predictors 
and the probability of an outcome is nonlinear.[11]  Fourth, since GEE is not based upon maximum 
likelihood theory, we could not utilize standard methods used with maximum likelihood-based 
regression to test model fit and compare models.[12]   
2. Subject-specific methods   
a. Random effects methods: Logistic regression models would be the most 
conventional approach for studying our dichotomous yes/no outcome.  We used Stata’s logistic 
function to model adverse event risk on antibacterial drug use. , We decomposed antibacterial 
drug exposure into between practice and within practice exposures; and we used robust variance 
estimators to adjust standard errors for clustering by practice.   
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A potential limitation of these methods is that logistic models cannot make use of data 
from practices with zero outcomes. If the risk of an adverse event without antibacterial drug 
exposure is zero, the odds of an adverse event without antibacterial exposure is also zero.  No 
matter what the odds of an adverse event with antibacterial exposure, the denominator of the 
odds ratio will be zero, and thus there will be no odds ratio result for this practice. This will also be 
a problem with some practices with non-zero outcomes if the outcomes are all in the exposed 
group, giving a non-zero odds in the numerator, but the odds for the unexposed would still be 
zero.  We would thus lose all information from these practices with zero odds in the unexposed. 
As discussed above, there is reason to believe that practices with zero odds in the unexposed 
may be different from practices with more adverse event outcomes, and, this method could 
provide biased estimates of our true conditional within-practice effect of interest.   
b. Mixed effects methods: Mixed effects conditional regression models 
could provide estimates of both fixed and random effects.  This could be accomplished with Stata’s 
xtmelogit, or Stata’s xtlogit and xtreg, using the mle option.  However, we were not necessarily 
interested in modeling the random effect of practice in the association of the antibacterial drug and 
adverse events, we were interested in the within-practice effects, as explained above.  In addition, 
random effects models can be very slow and cumbersome and would not be the most efficient for 
our research problem.    
c. Fixed effects (stratified) methods: Fixed effects logistic or linear models 
can allow random intercepts for the individual practices, allowing us to estimate within-practice 
effects of interest.  
i. Conditional fixed effects logistic regression models: Conditional 
fixed effects logistic models could decompose within- and among- practice associations between 
antibacterial drug use and adverse events.  Using Stata’s clogit and xtlogit functions, we modeled 
adverse event risk on antibacterial drug use, conditioning on practice.  As discussed above, a 
potential limitation of these logistic methods is that logistic models cannot make use of data from 
practices with zero outcomes.  
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ii. Conditional fixed-effects linear regression models: Similar to 
conditional logistic regression models, linear conditional models could provide fixed effects 
estimates, conditioning on practice.  This model would be inappropriate with a non-rare 
dichotomous outcome.  However, our outcome was sufficiently rare that all estimated outcomes 
would be <1.  As our anticipated effect size (risk) is small, there should not be an important 
difference using an additive instead of a multiplicative model.  Using linear regression we could 
operate on the risk-difference scale; this allowed us to make use of information from practices with 
zero outcomes, similar to what can be done with meta-analysis of very rare outcomes.[13, 14]  
Conditional linear regression, using Stata’s xtreg, can fit fixed effects longitudinal models with linear 
outcomes.Using Stata’s xtreg, we again decomposed within- and among-practice effects,  This 
result should be similar to using area average as an instrumental variable in helping to control for 
confounding by cluster.[14] 
As these methods are based upon maximum likelihood theory, we used standard 
methods to test model fit and compare models, including the likelihood ratio test and Akaike’s 
Information Criterion (AIC). 
 
C. Methods to adjust for confounding 
1. Confounding by measured variables 
a. Propensity Score analysis: 
  Propensity scores can be useful for modeling rare outcomes with common treatments.[5, 
15-17]  They have been used in observational studies to assure that potential confounders are 
balanced within the treatment and control groups being compared.  In propensity score analysis, 
the risk of outcome is estimated for treated vs. untreated patients within strata of patients with the 
same propensity for being treated, based on their other measured covariates.  However, standard 
propensity score analysis is far from ideal for this study.  We are concerned with two different 
levels of confounding: within-practice confounders and between practice confounders.  If, as 
expected, antibiotic exposure is heavily related to practice, we could need a separate propensity 
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score model within each practice. This need might arise if, for example, for a given patient 
indication, clinicians at two different practices might prescribe antibacterial medications at 
different rates.  A propensity score developed with patient-level factors but across all practices 
might balance poorly within practices.  Thus, to achieve covariate balance might require inclusion 
of different important variables and their interactions in different practices, as well as variable-by-
practice interaction terms, which could be quite cumbersome, if not impossible.  Then, we would 
also need to adjust further for between-practice confounders.  As we don’t have adequate 
physician-level data here, we were missing that dimension, and our models’ performance were be 
handicapped by this limitation.   
 We determined the probability of antibacterial drug exposure within each practice, 
defined as the propensity score for each practice, using the same covariates for each propensity 
score.  We performed multivariable analysis, considering several options for utilizing the 
propensity score:  Additional covariates could be added to models in addition to the propensity 
score as needed.   
1. Matching by propensity score [18-20]: This was not a good option for our 
study as exposure is extremely unbalanced between practices; matching would be difficult, and 
many visits would likely be unmatched, and thus not included in the analysis.   
2. Stratifying by propensity score: We stratified the propensity score for 
each practice into quantiles and then compared outcomes for treated vs. untreated visits within 
each propensity score stratum. [15, 20] 
3. Using the propensity score directly in the model as a covariate[20]. This 
should result in estimates similar to those using xtlogit above, decomposing estimates into 
within- and among- practice effects.   
4. Using a weighted propensity score with inverse probability of  treatment 
weighting,[21] assigning a [pw=weight] for each ARI visit equal to 1/propensity score for that 
practice if an antibacterial drug was received, and equal to 1/(1-propensity score) if an 
antibacterial drug was not received.  We explored using this propensity score method within our 
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conditional fixed effects model.  
The purpose of pursuing these methods was to allow us to simultaneously control for 
patient-level and practice-level factors, to have strata that reflected groups of practices with similar 
propensity to prescribe antibiotics, and to have sufficient numbers of adverse events within strata to 
avoid zero-cell problems.   
2. Confounding by unmeasured variables 
a. Instrumental variable analysis::  
The analyses described above could help control for measured confounders but would 
not address confounders that are unmeasured.[5] An instrumental variable (IV) is an observable 
factor related to treatment choice but that is not related to study outcomes either directly or 
indirectly through pathways through unmeasured variables, except through its effect on 
treatment.  Thus, an IV can be considered a variable that induces, or simulates, random variation 
in the study treatment assignment.[22]  If a suitable instrument can be found, it can help adjust for 
unmeasured confounders.[23-25]  An IV relies on the following assumptions: First, an IV should 
affect treatment, or be associated with the treatment through their mutual association with a 
common cause.  Second, an IV should be unrelated (or randomly associated with) patient 
characteristics. An third, an IV should be related to the outcome only through its association with 
the treatment.  If an adequate instrumental variable (IV) can be identified, an IV technique can 
help control for unmeasured confounding.   
Visit provider prescribing history was likely to be associated with the probability of 
exposure and unlikely to be associated with adverse event outcome, except through the exposure 
of interest, antibacterial medications; provider prescribing history was thus a candidate for 
instrumental variable.  Ideally, we could perform an instrumental variable analysis, using the past 
prescribing history of the visit provider as the instrument, including the other covariates.  We 
could consider that provider’s most recent previous ARI treatment as an instrument (antibacterial 
treatment vs. none)[23, 24], that clinician’s antibacterial prescribing rate,[14] and/or whether that 
clinician is a high vs. low antibacterial prescriber.[18]  However, unfortunately, prescriber is not a 
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reliable field in THIN (Bhuller, H, personal communication, October 6, 2008).  Alternatively, 
practice could be used as an instrument; as we expect that practice may be highly correlated with 
exposure.  We explored whether IV methods can provide estimates of fixed effects results, 
conditional on practice.   
b. Randomization-test based inference 
In randomization inference, each subject has two potential responses, the response 
observed if the subject was assigned to treatment, and the alternative response observed if that 
same subject were assigned to control, or no treatment.  The treatment effect tau is defined as 
the difference in outcome between a treated individual and the alternative potential outcome if 
that same individual was untreated.  If we assume no hidden bias, and an additive treatment 
effect, there is a constant treatment effect tau such that every subject would have the same tau if 
treated with antibacterial drugs vs. if that subject was untreated.  Control responses might vary 
from subject to subject, but treatment should change the outcome by the same amount.  Our null 
hypothesis was that, adjusted for covariates, if there was no hidden bias, treatment status was 
distributed randomly with respect to outcome.  The alternative hypothesis is that there was a 
significant relationship between outcome and treatment status.[5, 26]   
The potential benefit of randomization-test-based methods is that they are assumption 
free, i.e., they do not rely on the assumptions behind any model.  Nor do they rely on large 
sample theory as a basis for variance estimates [27, 28]  But these methods are not without 
challenges. 
First, in the application of interest, the outcomes across multiple clinical practices, 
randomization-test-based methods must consider the possibility of confounding by practice.    We 
would need to consider the choice of a test statistic with this potential for confounding in mind.    
Second, the outcomes in this study were rare.   Care must be taken that the method chosen does 
not unintentionally drop practices because no events occur.  Third, although randomization-test-
based methods control for Type I error, the study of adverse events demands special attention to 
power (or Type II error).    
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Several alternative methods for implementing randomization-test-based methods could 
be compared with model-based methods.   An initial issue is whether the effect of exposure is to 
be expressed on a multiplicative score (as with an odds ratio) or on an additive scale (as with a 
risk difference).  A key exposition on the use of randomization-test-based methods for multicenter 
data with binary outcomes,[27] assumes that the effect should be measured on an additive scale.  
But the methods should not be confined to additive estimates.   
Stratified rank based methods as described by Rosenbaum [26] (section 7) and Small, 
[29]  rely less on statistical models to obtain a test statistic, while they allow use of regression 
methods to adjust for covariates.  However, these methods would not be straightforward to 
implement for this study as they rely on grid searches and inverting test-statistics[30] (section 9.2) 
to obtain point estimates and confidence bounds, would have had to be adapted for binary 
outcomes, and would need to address confounding by practice.   Thus, we do not include these 
methods in our analysis but plan to address this topic in a future project.   
We compared our results obtained using the methods described above. 
c. Simulations:  
When we use simulated data, in contrast to when we use real data, we know the 
underlying true parameter values and have complete control over the data structure.  A simulated 
dataset is relatively easy to construct, and, while simplistic, can be structured to reflect almost 
any type of underlying data values and distribution.  We can examine the effect of varying one 
parameter at a time, or multiple parameters in combination, holding everything else constant.  
Simulations can help us explore what happens to our expected bias and power as we vary our 
data structure and model assumptions throughout an endless variety of possible variations, and 
how robust our coverage and power are to our model assumptions..  We generated simulated 
datasets using known distributions for patient-level parameters of interest to reflect conditions 
similar to our data: large (~2 million visits relevant to the study of antibacterial drug use) highly 
hierarchical (200 practices), extremely unbalanced exposure across clusters (practices), and rare 
outcomes with lots of zero-outcome cells.  We compared the performance of the different types of 
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models described above in describing the stipulated values in terms of bias and power with very 
rare events and highly clustered data.  We also used these simulations to explore the effect of 
different levels of data clustering, the influence of parameter variability between clusters, and how 
robust our results were to confounding due to unmeasured variables.   
Each practice was stipulated to have a different baseline rate of antibacterial drug use, 
with a mean risk of antibacterial drug exposure of 0.60 (60%), and a standard deviation of 0.2 
(20%) across practices.  Each practice was stipulated to have a different baseline risk of an 
adverse event, with a mean of 0.0000866 and a standard deviation of ± 0.00005 on the additive 
scale.  Based upon preliminary data (Chapter 6), the parameter for the difference in rare severe 
adverse event risk for those exposed to antibacterial drugs vs. for those not exposed was 
stipulated at  -0.0000411 (a protective effect of 4.11 per 100,000 exposures).  Each practice was 
stipulated to have a different baseline risk of the continuous covariate (for example, centered 
weight, with a mean of 0 and a standard deviation of 15 kg.).  This covariate was modeled both 
as a true confounder, associated with both exposure and outcome (beta=25 and beta = 
0.0000045871, respectively), and a noise covariate, not associated with exposure but included in 
the model for the outcome (same beta = 0.0000045871).   
 Using the simulated datasets, we implemented Stata’s xtreg to develop a conditional 
fixed effects linear model, modeling the risk of severe adverse event on antibacterial drug 
exposure using 200 simulations and an alpha of 0.05.  For each run, we report the mean of the 
regression slopes from the simulation model, which is the risk difference for adverse event 
comparing antibacterial exposed vs. unexposed visits, to compare with the stipulated slope used 
to generate the data.  We also report the number of zero-event practices, and the estimated 
power of the model to show a difference in adverse event risks between antibacterial-treated and 
untreated visits.   
Our primary analysis used 200 practices (clusters) with 10,000 patient visits each, 
variable antibacterial drug exposure and adverse event risk between practices, and no 
unmeasured covariates.  For subsequent analyses, we varied the number of practices from 50 
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practices with 40,000 visits per practice up to 400,000 practices with 5 visits per practice, holding 
the total number of visits constant at 2,000,000.  We also explored the effect on the parameter 
estimate and power of eliminating the variability in exposure and/or outcome risk, and using a 
multiplicative conditional fixed effects logit model (Stata’s xtlogit) for simulation estimates instead 
of an  additive model (Stata’s xtreg).   
 





































































































A. Description of the cohort 
 Our cohort contained 1,646,229 total visits and 1,531,019 grouped visits by 814,283 
patients.  The mean number of grouped visits per patient was 1.9 (median 1, range 1 to 88 visits).  
There were 495,129, 164,447, 70,145, 34,373, 18,466 and 748,479 patients with 1,2,3,4,5, and 
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There were 326 practices included in the cohort. The mean number of grouped visits per practice 
was 4696.4 (median 3232.5, range 24 to 27,190, Table 7 and Figure 7) 
 



















































Overall, patients at 65.4% of ARI visits received antibacterial drug prescriptions.  As 
expected, antibacterial prescribing varied widely between practices, from a low of 3.1% to a high 
of 94.7% of grouped visits receiving antibacterial drug prescriptions (Figure 8).  
 





























Antibacter ial Drug Use for Acute Nonspecific Respiratory Tract Infections
 
 
This extreme imbalance of antibacterial drug prescribing across practices provided strong 
evidence that we needed to address any clustering and confounding by practice.  There was not 
a strong association between the number of visits and antibacterial drug use by practice (r=0.227, 







Figure 9. Antibacterial Drug Use for Acute Nonspecific Respiratory Tract Infections vs. 
Number of Visits, by Practice 
  
The outcome was extremely rare with a mean incidence rate of 7.71 per 100,000 
grouped visits (8.87 ungrouped, Figure 10). There were 244 practices with zero severe adverse 
event outcomes within 14 days of grouped visits and 58, 16, 5, 2, and 1 practices with 1, 2, 3, 4, 
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Severe Adverse Event Risk after Acute Nonspecific Respiratory Tract Infection Visit
 
Figure 11. Severe Adverse Events after Acute Nonspecific Respiratory Infections, by 



































Table 8. Severe Adverse Events within 14 Days of Visit for Acute Nonspecific Respiratory 
Tract Infection, Grouped Visits 
Severe Adverse Events within 14 Days of Acute Nonspecific 
Respiratory Tract Infection Visit,  
Grouped Visits  
Severe adverse 
events 










This extreme imbalance of outcome by practice, particularly with many practices (74.8%) 
experiencing zero outcomes, provided support that we were most likely to achieve unbiased 
results if we could include information from practices with zero outcomes in the analysis.  
 
B. Methods to model conditional rare outcomes 
1. Marginal Models 
Generalized estimating equations 
 Using GEE, with the panel variable specified as patient, the time variable specified as 
patient’s visit number during the cohort, and an exchangeable correlation structure, the 
unadjusted odds ratio of a severe adverse event within 14 days of the index visit was 1.07 (95% 
confidence interval 0.73 to 1.57, p=0.73), Table 9, for patients prescribed vs. for those not 
prescribed antibacterial drugs; as described above, this is a marginal, or population-averaged 




score, and neighborhood racial mix, the covariates, aside from practice, found to be confounders 
in this model, the OR was 0.82 (95% c.i. 0.55 to 1.23, p=0.34), Table 9 .  Substituting an 
independent correlation structure, the OR was unchanged.  However, we found that GEE 
required too large a memory size to allow us to specify practice as the panel variable.  An 
alternative approach would be to adjust for practice as a categorical variable, however this model 
would not converge with our data, even without any additional covariates.  GEE apparently did 
not allow us to adjust for confounding by practice, and thus cannot be relied upon to provide an 
unbiased estimate of the true relationship between antibacterial drug use and adverse events.  
However, despite this limitation, for our problem, GEE provided similar results to the potentially 
more robust methods described below.   
 
2. Subject-specific methods 
Random effects methods: 
Logistic regression: Using logistic regression we began to decompose the effects of within-
practice vs. across- (or among) practice antibacterial drug exposure.  We modeled adverse event 
risk on antibacterial drug use, using robust variance estimators to adjust for clustering by practice, 
and decomposing antibacterial exposure into between-practice and within-practice exposure.  
The unadjusted odds ratio of a severe adverse event within 14 days of the index visit for visits 
exposed vs. those not exposed to antibacterial drugs was 1.07 (95% c.i. 0.72 to 1.58, p=0.74), 
Table 9.  Adjusted for centered year, the number of different classes of drugs used in the 
preceding year, the number of visits during the preceding year, and neighborhood racial mix, the 
conditional within-practice odds ratio of a severe adverse event within 14 days of the index visit 
for visits exposed vs. those not exposed to antibacterial drugs was 0.79 (95% c.i. 0.51 to 1.22, 
p=0.29), Table 9.   
 
Fixed effects (stratified) methods: conditional regression  
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Conditional logistic regression: Implementing conditional logistic regression using Stata’s clogit 
command, with practice as the group variable, the unadjusted odds ratio of a severe adverse 
event within 14 days of the index visit for visits exposed vs. those not exposed to antibacterial 
drugs was 0.92 (95% c.i. 0.61 to 1.38, p=0.67), Table 9.  Adjusted for the number of different 
classes of drugs used in the preceding year, the odds ratio was 0.81 (95% confidence interval 
0.54 to 1.22, p=0.32).  However, data from 244 zero-outcome practices out of 326 total practices, 
including 842,712 out of 1,531,019 total visits were dropped.  There is strong reason to suspect 
that practices with zero outcomes may differ in important ways from practices without zero 
outcomes; to the extent that these differences were unmeasured, we cannot adjust for them, and 
thus these very limited results, only including data from practices with positive outcomes, are at 
risk of being significantly biased.  Thus, in our effort to estimate the within-practice effect of 
antibiotic exposure, here we are inherently constrained to use only those practices with both 
events and with some variation at the patient level in the use of anbiotics.  
We next used Stata’s xtlogit to fit multiplicative logit conditional fixed effects models, 
decomposing antibacterial drug exposure to examine within- rather than between-practice effects.  
The unadjusted OR for a severe adverse event for patients exposed vs. unexposed to an 
antibacterial drugs was 0.92 (95% c.i. 0.61 to 1.38, p=0.67, identical to the results using the clogit 
command, above).  Adjusted for the number of different drug classes prescribed during the past 
year and Townsend score, the OR was 0.77 (0.50 to 1.17, p=0.22), Table 9.  Similar to 
conditional logistic regression using clogit, a limitation of this method is that xtlogit could not make 
use of data from practices with zero outcomes (giving an odds of zero for severe adverse events 
without antibacterial drugs, and a zero denominator for the odds ratio), and thus lost all 
information from 780,333 visits (55% of the visits!) from these 238 practices with this method; 
again, the data from the practices with zero events are likely to be different in many respects from 
data from practices with non-zero events; to the extent that these events are not distributed 




Conditional linear regression 
 Stata’s xtreg was used to fit additive linear conditional fixed effects models.  As xtreg is 
estimating risk differences, unlike estimating odds ratios using xtlogit’s multiplicative model where 
zero-event practices drop out because of unusable zero denominators, information from zero-
event practices is used in the xtreg estimates’ additive model.  Thus, with xtreg, we could take a 
more comprehensive look at the influence of potential clustering and confounding by practice 
using all of the data.  First using subject as the panel variable, and using the mle option, our 
random effects estimate for the unadjusted risk difference for a severe adverse event for patients 
exposed vs. those unexposed to antibiotics was 0.511 per 100,000 visits (95% c.i. -2.41 to +3.44, 
p=0.73), Table 9, note that the point estimate was positive.  Using the fe option, again 
decomposing antibacterial drug exposure to examine within-patient vs. between-patient exposure 
effects , our unadjusted conditional (on patient) fixed effects estimate for the risk difference for a 
severe adverse event for patient visits exposed vs. unexposed to antibacterials was -0.145 per 
100,000 visits (-5.03 to +4.74, p=0.954), note the point estimate, conditioning on patient, was 
negative.   
 Using practice as the panel variable, with the mle option, our random effects estimate for 
the unadjusted risk difference for a severe adverse event for patients exposed vs. those 
unexposed to antibacterial drugs was the same, of course, as with patient as the panel variable: 
0.511 per 100,000 visits (95% c.i. -2.41 to +3.44, p=0.73), Table 9.  Using the fe option, the 
unadjusted conditional  (on practice) fixed effects estimate of the risk difference for a severe 
adverse event for patients exposed vs. those unexposed to antibacterials, was -0.6777 per 
100,000 visits (95% c.i. -3.83 to +2.47, p=0.67).  Thus, using the mle random effects model, 
ignoring potential confounding by patient or practice, antibacterials appeared to increase the point 
estimate for the risk of adverse events, while, using the model conditional on practice or patient, 
antibacterials appeared protective!  This is evidence that confounding by patient and practice is 
very important here!   
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 This confounding may not have been a serious problem at the patient level, as we had 
many potential measured patient-level covariates to include in the model.  However, at the 
practice level, there were fewer options for covariate adjustment.  Unfortunately, prescriber is not 
a reliable field in THIN (Bhuller, H, personal communication, October 6, 2008).  The practice-level 
variables available in THIN, such as the Townsend score (missing for 8.2% of our visits), and the 
racial/ethnic mix of the population served (missing for 4.4% of our visits), are somewhat 
inconsistently available, and less directly related to the encounter between the patient and 
physician during the visit than individual characteristics of the specific patient and physician 
involved.  With prescribing extremely unbalanced across practices, as discussed above and 
shown in Figure 6, confounding by practice appeared to be of extreme importance and our 
models needed to adjust for this to obtain unbiased estimates for our outcome of interest.   
 Using xtreg with the fe option, and practice as the panel variable, adjusted for age, year, 
the number of different classes of drugs and the number of office visits within the year prior to the 
visit, and the Townsend score, the conditional fixed effects estimate for the risk difference for 
severe adverse event for patients exposed vs. those unexposed to antibacterial drugs was -1.42 
per 100,000 (95% c.i. -4.75 to +1.91, p=0.40) Table 9. We found an interaction between 
antibacterial exposure and the number of different classes of medications used in the previous 
year, expressed as quintiles.  Adjusted for age, year, the number of different classes of drugs and 
the number of office visits within the year prior to the visit, and the Townsend score, the risk 
difference for severe adverse event for patients exposed vs. those unexposed to antibacterials 
was significant only for the highest quintile of drug use during the previous year: -29.14 per 
100,000 visits (95% c.i. -44.98 to -13.29, p<0.001).    
 
C. Methods to adjust for confounding 
Propensity score analysis 
Using a propensity score presents a particularly interesting challenge for this problem.  If 
we generated a propensity score in the typical fashion, we would have used a common 
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propensity score model across each of our 326 practices. However, this type of model would 
have been wildly inappropriate here, as we know that the propensity for antibacterial exposure 
varies so extremely between practices (Figure 8).  In order to develop a propensity score that is 
actually helpful in modeling the propensity for antibacterial drug exposure, we needed, as noted 
previously, to model a separate propensity score for each practice.  A separate propensity score 
for antibacterial drug exposure for each practice was modeled using Stata’s pscore command 
with the following covariates: sex, age, visit year, the number of comorbidities at the time of the 
visit, the number of different classes of medications prescribed and the number of office visits 
during the year prior to the index visit, and patient smoking history.  In order to get the propensity 
score models to successfully converge, we needed to dichotomize our continuous covariates, and 
we were still not able to generate propensisty scores for eleven of the 326 practices (including 
90,885 of 1,531,019 visits).  In theory, it might have been difficult to generate pscores for 
practices with very low use of antibacterial medications, however that did not seem to fully explain 
the problem here.  Mean use of antibacterials among omitted practices was 68.2% (range 50.6% 
to 83.1%) compared with 65.4% for all practices, using grouped visits.   
Because our propensity score analysis was limited to visits from practices with propensity 
scores, for comparison, we fitted the xtreg model adjusted for age, year, number of drugs and 
number of visits during the past year, and Townsend score, as above, but only included visits 
from practices with fitted propensity scores, eliminating those 90,885 visits without propensity 
scores.  The adjusted conditional fixed effects estimate for severe adverse event for patients 
exposed vs. those unexposed to antibacterial drugs was again significant only for the highest 
quintile of drug use during the previous year, when antibacterial use was again protective with a 
risk difference for those exposed vs. unexposed of -30.56 per 100,000 visits (-47.17 to 113.96, 
p<0.001) (this estimate was slightly farther away from the null than the point estimate of  -29.14 
per 100,000 visits, using data from all of the practices described above), Table 9. 
 Using the propensity score as a continuous variable, the risk difference for 
adverse event for exposed vs. for unexposed patients was again significant only in the highest 
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drug use quintile, with a risk difference of -32.62 per 100,000 visits (95% c.i. -49.21 to -16.03, 
p<0.001), very similar to the comparison point estimate, above, without the propensity score of --
30.56 per 100,000 visits.  However, this model assumed a linear relationship between our severe 
adverse event outcome and our propensity score.  A model stratified by propensity score will 
make fewer assumptions in this regard.   
Dividing our propensity score across quintiles, we used the propensity score quintile as a 
categorical variable, essentially stratifying (subclassifying) by propensity score, comparing the 
risk of an adverse event for exposed vs. for unexposed patients within quintiles of the propensity 
to have been prescribed an antibacterial drug, and conditional on practice.  Using xtreg, the fixed 
effects estimate of the risk difference for severe adverse event for exposed vs. unexposed 
patients, conditional on practice, and adjusting for Townsend score was again significant only for 
the stratum of patients who are in the highest quintile of medication use, and antibacterials were 
again protective with an estimated risk difference of -32.62 per 100,000 visits (95% c.i. -49.22 to -
16.03, p<0.001), very close to our estimate of  -30.56 obtained without the propensity score, 
Table 9.   
Because our panel variable was practice, we were unable to utilize the propensity score 
with an inverse probability of treatment weighting approach, as our treatment weights could not 
be constant within practice. This was a limitation of this method for our type of analytic problem.   
 
Instrumental variable analysis 
As discussed above, if a strong instrumental variable can be identified, an instrumental 
variable technique can help control for unmeasured confounding.  However, unfortunately, our 
best candidate for a strong instrumental variable, visit provider prescribing history, is not reliable 
field in THIN, as discussed above.  Alternatively, practice could be used as an instrument; as we 
have shown that practice is highly correlated with exposure.   
Using Stata’s ivregress function, we performed 2-stage least squares regression, 
modeling practice on Townsend score, racial/ethnic mix, and visit year, and then using practice as 
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an instrument in a linear regression modeling severe adverse event on antibacterial drug 
exposure, adjusting for age, visit year, number of different classes of medications used in the past 
year, and number of office visits in the past year. Again, the risk difference for antibiotic exposed 
vs. for unexposed visits was significant only in the highest quintile of medication use, and was 
again protective here in the IV model, with a point estimate of -28.11 per 100,000 visits (98% ci. -
43.93 to -12.29, p<0.1001), Table 9.  This is similar to the type of result Stukel et. al. obtained, 
using instrumental variable regression, with Stata’s ivregress to examine the effects  of invasive 
cardiac management on survival after acute myocardial infarction.[14]  They used regional cardiac 
catheterization rate as an instrumental variable, as it is thought to be highly correlated with 
treatment but not to effect the outcome independently of the exposure of interest.  Their result 
estimates the treatment effect on the marginal subjects, or those who would receive treatment in 
high-prescribing but not low-prescribing regions.  Thus, their result describes between- region, and 
not within-region risks.  The counterfactual contrast of interest would be what would be the effect 
of catheterizing vs. not catherizing on the same patient at the same time, in the same region, or 
the within-region contrast.  
Our fixed effects model using xtreg conditional on practice should provide less biased 
estimates compared with this instrumental variable method, by helping to control for confounding 
by practice.[14]  That model’s risk difference estimates were similar to the methods obtained using 
IV methods.   
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Table 9. Regression Results Summary 
Regression Results Summary 
 Unadjusted Adjusted 
Method Point 
estimate 




95% c.i. P 
value 
GEE       
   Patient = group 1.07 0.73 to 
1.57 
0.73 0.82 0.55 to 1.23 0.34 
   Practice=group X X X X X X 
Logistic regression 1.07 0.72 to 
1.58 
0.74 0.79 0.51 to 1.22 0.29 
Clogit 0.92 0.61 to 
1.38 
0.67 0.81 0.54 to 1.22 0.32 
Xtlogit 0.92 0.61 to 
1.38 
0.67 0.77 0.50 to 1.17 0.22 
Xtreg       
  Panel = subject       
      Not conditional on subject 0.511 per 
100,000 
visits 
. -2.41 to 
+3.44 
0.73    





p=0.954    
   Panel = practice 
          Not conditional on practice 





0.73    










For highest quintile of drugs within past year          Conditional on practice, interaction    
-29.14 per 
100,000 visits 
. -44.98 to -
13.29 
p<0.001 
For highest quintile of drugs within past year             Conditional on practice but only visits 
with propensity scores 
-1.45 -4.96 to 
+2.06 
0.419 
-30.56 per -47.17 to <0.001 
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100,000 visits 113.96 
For highest quintile of drugs within past year           Propensity score as continuous 
variable  for visits with propensity scores 
   
-32.62 per 
100,000 visits 
. 49.22 to -
16.03 
<0.001 
For highest quintile of drugs within past year          Propensity score as quintiles  for visits 
with propensity scores 








Instrumental variable -0.290 -3.54 to 
+2.96 








As described above, our dataset was large (1,646,229 visits) highly hierarchical (326 
practices) with a relatively common and variable exposure across practices (patients at 65.4% of 
visits received antibacterial drugs, ranging from 3.1% to 94.7% depending on practice), and a very 
rare and variable outcome across practices (severe adverse event risk of 7.71 per 100,000 visits, 
ranging from 0 to 280.9 depending on practice).  We compared the performance of our conditional 
fixed effects linear model (using xtreg) under varying conditions and assumptions, and compared 
these results with those using a conditional fixed effects logistic model (using xtlogit) conditional 
fixed effects logit model, using simulated datasets, generated to reflect conditions similar to our 
data: large (2 million visits), highly hierarchical (ranging from 50 to 400,000 practices with 5 to 
40,000 visits per practice), a relatively common and variable exposure across practices, and a rare 
outcome (specified to be 8.66 per 100,000 visits, with a risk difference of -0.0000411 (-4.11 per 
100,000 visits) for the protective effect for exposed vs. unexposed visits);  many practices thus 
included zero outcomes.   We explored the effect of increasing the number of practices on expected 
power, holding the total sample size constant; with an extremely rare outcome, as the number of 
practices increases we would expect an increase in power due to the design effect, but may see a 
decrease due to an increased number of zero-event practices. We also used these simulations to 
explore how robust our results and our power were to ignoring or mis-specifying the variability in the 
models’ estimated parameters, and confounding due to unmeasured variables.   
For a baseline analysis, with our primary seed, using 200 practice with 10,000 visits per 
practice, the mean regression slope from the simulated data  was -3.72 per 100,000 visits, 
compared with the true value of -4.11 used to generate the data, or a 9.5% bias toward the null 
value of the slope =0, Table 10.  The power to find this difference in slope using this model was 
estimated at .81, and there were 112.93 practices with zero adverse events (zero-event practices).  
Using a different seed, this same model yielded an estimated mean regression slope of -3.817 per 
100,000 visits, or a 7.1% bias toward the null, with a power of 0.885, with 87.68 zero-event 
practices.   
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Decreasing the number of practices from 200 to 100, we found an estimated mean 
regression slope of -3.86 per 100,000 visits, or a 6.1% bias toward the null, with a power of .875.  
Decreasing the number of practices still further to 50, the estimated mean regression slope was -
3.814 per 100,000 visits, a 7.2% bias toward the null, with a power of 0.82 (Figure 12 and Table 
10).  Power and bias estimations using additional practice sizes are shown in Table 10 and Figure 
12.  As shown, we did not see the increase in power to detect our very small risk difference that we 
would expect from the design effect with increasing numbers of practices, in fact, power stayed 
about the same despite large increases in the number of practices in the model.  The power 
suffered from the progressively increasing numbers of zero-event practices seen, as the number of 
visits per practice decreased with increasing practice size, holding total visits constant, 
demonstrated in Table 10.  With increasing numbers of zero-event practices, it gets progressively 
more difficult to show significant differences between antibacterial-exposed and –unexposed visits 
within each practice.   
 





 When we eliminated the baseline variability of antibiotic prescribing between practices, 
the mean estimated slope was -3.741 per 100,000 visits with a bias of 9.0% toward the null, and 
a power of 0.875 (Table 10).  When we eliminated the baseline variability of adverse event risk 
between practices, the mean estimated slope was -4.063 per 100,000 visits, with a bias of 1.1% 
toward the null and a power of 0.92.  When we eliminated both the baseline variability of 
antibacterial drug prescribing and the baseline variability of adverse event risk between practices, 
the mean estimated slope was -4.089 per 100,000 visits with a bias of only 0.5% toward the null 
and a power of 0.935.  This implies that, if baseline variability between cluster groups is ignored 
for power estimation, we risk potentially grossly overestimating our power to detect a difference 
between groups, especially when we ignore potential variability in rare outcome risk between 
clusters.  This effect also makes us vulnerable to quite biased results from errors in measurement 
of exposure or outcome.   
 When we consider the impact of unmeasured covariates, adding a confounder as 
described above, and ignoring this (unmeasured) confounder in the analysis, resulted in an 
estimated mean slope of +4.741 per 100,000 visits, an over 200% bias and a point estimate for 
the risk difference in the opposite direction, indicating a risk from antibacterial drug exposure 
rather than the stipulated true protective effect, with a power of 0.71. (Table 10)  If the same 
unmeasured covariate is not a confounder but merely a noise variable, associated with the 
outcome but not with the exposure, the estimated mean slope was -3.998 per 100,000 visits, a 
2.7% bias toward the null, and a power of .72 (Table 10).   Thus, an unmeasured covariate will 
obviously effect power; if the covariate is a noise variable, our point estimate will be relatively 
unbiased, but we would have less power to show a difference, but if the unmeasured covariate is 
a confounder, there is a risk of obtaining an extremely biased result!   
 Finally, given the stipulated simulated data, our stipulated risk difference for severe 
adverse event of -4.11 per 100,000 visits in antibacterial drug exposed vs. unexposed visits 
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should correspond to an odds ratio of 0.5357.  Using xtreg instead of xtlogit, we found an odds 
ratio of 0.574, biased 7.1% toward the null, similar to our xtreg results, with a power of 0.80.  
 
Table 10. Simulation Results 
Simulation Results 
200 reps, 2,000,000 total patient visits, α = 0.05, Risk difference specified at -0.0000411 or -
4.11 per 100,000 visits with antibacterial drug exposure 








Power Number of 
zero-event 
practices 
Linear regression, conditional on practice 
Variable antibacterial drug exposure and adverse event risk between practices 
No 
unmeasured 
covariates 50  40,000 ‐3.814 0.82 
↓ 
100  20,000 ‐3.86 0.875 
↓ 
200  10,000 ‐3.72 0.81  112.93
↓ 
400  5000 ‐3.623 0.795  293.26
↓ 
500  4000 ‐3.983 0.865  387.29
↓ 
667  3000 ‐3.661 0.79  550.74
↓ 
800  2500 ‐3.92 0.855  679.72
↓ 
2000  1000 ‐3.612 0.8  1871.18
↓ 
4000  500 ‐3.761 0.83  3869.355
↓ 
8000  250 ‐3.864 0.855  7866.1899
↓  62500  32 ‐3.555 .795  62364.578
↓ 
400000  5 ‐3.658 0.785  399858.28
Unmeasured 
confounder 200  10,000 +4.741 0.71  51.73 
Unmeasured 
noise 
covariate 200  10,000 ‐3.998 .72  86.25 







200 10,000 -4.063 .92 





200 10,000 -3.741 .875 




200 10,000 -4.089 .935 
Logistic regression, conditional on practice 
Risk difference = -0.0000411 or 4.11 per 100,000 visits, odds ratio = 0.535 




200 10,000 Odds ratio = 0.574 0.80 112.93
 
Discussion 
 Our data presented at least three major analytic challenges. First, exposure, outcomes, 
and covariates were extremely clustered by practice.  Second, antibacterial drug prescribing and 
outcomes were extremely unbalanced among practices. Third, our outcome was exceedingly 
rare, resulting in many practices with zero outcomes.  Overall, despite the method used, as long 
as we decomposed within- from between-practice results, we obtained similar results for our 
outcome of interest, the within-practice estimates.   
 GEE had a large memory requirement which made it cumbersome to perform complex 
analysis, even without additional covariates.   
 Conventional and conditional logistic regression did not allow us to make use of groups 
with zero events; given our many practices and extremely rare outcomes, we would end up losing 
information from most of our data with logistic regression analysis, and to the extent that adverse 
outcomes were not distributed randomly across practices, risk obtaining biased outcomes.  On 
the other hand, logistic regression would appear the right choice based on theory; a multiplicative 
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model could be a more reasonable choice for our dichotomous outcome rather than an additive 
model.  
Conditional fixed effects linear regression models converged easily, and were able to 
make use of all of our data, even data from practices with zero outcomes.  As discussed above, 
this problem is similar to using meta-analysis to study data regarding rare events.  [13]  Results 
using this method for our rare binary outcome appeared relatively unbiased and stable using 
simulated datasets with known parameter estimates.   
Our results from the random effects conventional and conditional logistic regression 
models were quite similar to those from the linear regression models; as long as we focused on 
within-practice estimates; the bias and power of the logistic and linear models were virtually 
identical.  Somewhat counter-intuitively, although logistic regression was not able to make use of 
data from practices with zero outcomes, our power was essentially no different with linear 
regression as with logistic regression.  Thus, for the research question addressed in this study, 
the conditional logistic regression results were robust to losing data from zero-event practices. It 
is unknown whether this is specific to our particular question, or generalizable to other very large 
datasets with common exposures and rare outcomes.  Other investigators have shown with 
simulations that conditional logistic regression does not always give the best results, in terms of 
bias, coverage,and power, under conditions of rare dichotomous events.[7]  
The propensity score analysis was quite cumbersome; as propensity for antibacterial 
drug prescribing was so unbalanced between practices, we needed to model a separate 
propensity score for each practice.  Covariates for some practices were too unbalanced for the 
propensity score models to converge, and thus we were not able to use data from those practices 
in the propensity score analysis.  We were not able to utilize inverse probability of treatment 
weighting in Stata with our data clustered by practice.  However we used the propensity score, 
our point estimates for the effect of antibacterial drug exposure were similar to our estimates 
obtained using our other models.  Although the estimates using the propensity score models are 
close, they do not seem to provide much advantage to the non propensity score models, and do 
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not fully utilize all available information (for example, we had to dichotomize continuous variables 
and omit data).  
Unfortunately, we were not able to use provider prescribing history as an instrumental 
variable; practice seemed to be the strongest available potential instrument, and our results using 
other methods seem to adequately adjust for practice; IV methods did not seem to add any 
advantage to our other more straightforward methods yielding similar results. IV methods may 
suffer from some of the same limitations of propensity score analysis, in that some variables may 
be extremely unbalanced across the dataset, in a nonrandom manner.   Additionally, care must 
be taken when using IV methods that the analysis can decompose the effects to provide the 
contrast of interest; plugging data into an IV program may miss important effects, for example 
those due to clustering and confounding by site.  This is similar to the problem experienced by 
Stukel et. al, when they used Stata’s previous generation instrumental variable command to 
model mortality rates on cardiac catheterization, using regional cardiac catheterization rates as 
an instrumental variable.[20]  We obtain the between-practice (or between-region) rather than the 
within-practice estimates of interest using these instrumental variable methods.   
When planning a trial with clustered data. other parameters being equal, it should always 
improve our power to show a difference if we can include more patients in the study.  Adding 
more practices should further increase the power due to the design effect.  However, sometimes 
trade-offs need to be made between the number of practices included in the study, and the 
number of patients per practice.   We showed that, with our rare outcome, comparing many 
smaller practices with fewer larger practices, the usual advantage of having many practices for 
increasing power due to the design effect is at least partially outweighed by the increased number 
of practices with zero events, giving less power to make within-practice estimates.  In planning a 
study of rare outcomes, the advantages of using many practices with fewer patients each to 
maximize the design effect has to be weighed against the advantages of more patients, and thus 
more events, per practice using fewer practices with more patients each.   
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For reliable power calculations, we need good data on baseline risks, and good estimates 
of baseline variability between clusters, or practices, especially variability in rare outcomes 
between practices.  With baseline variability in exposure and outcome risk between practices, we 
need more data to show an effect, even if we are already adjusting for confounding by practice.  
We showed that ignoring baseline variability in exposure or outcome in power calculations can 
lead to extremely biased power estimates.  We also showed that omitting consideration of the 
effects of confounding variables from power calculations can have drastic consequences, 
resulting in loss of power and potential biased results.   
In summary, we showed that conditional fixed effects linear regression provided stable 
and relatively estimates of common exposure treatment effects on rare outcomes.  Although they 
were able to utilize all available information, even from groups with zero events, results using these 
models were quite similar to results obtained using more traditional methods for binary outcomes,.  
It is unclear that there is an obvious ‘best’ method for modeling rare events such as those modeled 
here, although it is reassuring that the different methods used yielded such similar results.  
Comparing the risk of very rare events between very unbalanced groups presents real challenges 
to power, even with very large datasets.  Additionally, if power estimations for observational studies 
of rare events ignore potential baseline variability between groups, and potential confounding 
covariates, results could be quite biased and power estimates may be grossly inflated.   
As The Health Improvement Network (THIN) as well as other electronic medical record 
databases continue to grow in number and size, experience and insights with effective and efficient 
methodologies for using observational data to explore rare outcomes will help us to exploit their 



















































































Chapter 6.Outcomes I, Potential Risks of Antibacterial Drug Use: Adverse events 
associated with adult antibacterial drug use   
In the U.S., we have virtually universal exposure to antibacterial medications; in the year 
2000, persons >age 15 received a total of 68,481,645 antibacterial drug prescriptions.  Every 
individual in the U.S. is prescribed a short-term course of systemic antibacterials once every three 
years to almost twice per year, on average, resulting from a visit to an ambulatory health care 
provider.[1-6]  Virtually everyone will be exposed to at least one course of antibacterial drugs 
during his/her lifetime.  It is doubtful that the U.S. population has such a high exposure to any 
other class of medications.  This extraordinarily high exposure to antibacterials should command 
careful vigilance to the consequences. Although the perceived risk of an adverse event related to 
antibacterial drug use may be low, with such a high level of prescribing, the population-
attributable risk of serious adverse drug events due to this medication class could be quite high.   
Antibacterial drugs are also among the most common drugs implicated in adverse 
events.[7-9]. Of particular recent interest are drugs that are suspected of increasing the risk of 
cardiac arrhythmia by prolonging the QTc interval and/or directly causing Torsades de Pointes; 
macrolides and fluorquinolones are frequently implicated in adverse events through this 
mechanism.[10]  Also of recent interest are drugs with suspected adverse events related to their 
relationship with the hepatic CYP3A4 pathway.  For example, macrolides are metabolized by the 
CP3A4 pathway and both macrolides and fluoroquinolones are inhibitors of the CYP3A4 pathway; 
this could heighten the risk of associated adverse events.[11, 12]   
 Most of these associations have been described with case reports and cases series; they 
almost never include a control group measuring adverse events in unexposed patients and thus 
the true absolute and relative risks of adverse events associated with these agents remain 
unknown.  A randomized clinical trial is considered the gold standard to best ensure comparability 
of measured and unmeasured confounding variables between exposed and unexposed 
subjects,[13] however opportunities and resources to perform large prospective randomized trials 
are limited.  Randomized trials to investigate subtle, rare, or complex effects would need to be 
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quite large, would be infeasible to perform for every important research question, and are not 
always ethical.[14]  Longitudinal observational data with individual-level links have the potential to 
help shed light on the outcomes of antibacterial drug use.   
Antibacterial drugs are often prescribed for acute nonspecific respiratory infections, 
despite the fact that they are unlikely to be of benefit; adults at about half of U.S. office visits for 
acute nonspecific respiratory infections receive antibacterial drug prescriptions.[3, 4, 15]  The 
UK’s The Health Improvement Network (THIN) primary care electronic medical record database 
contains large amounts of linked longitudinal clinical prescription and outcome data.  The 
objective of this study is to use a subset of the entire THIN cohort with an office visit for acute 
nonspecific respiratory infections to compare adverse event rates of antibacterial drug-exposed 
vs. antibacterial-unexposed patients.  By limiting the comparison to patients with acute 
nonspecific respiratory infection visits, we promote comparability between exposed and 
unexposed patients in the cohort.  However, in these analyses, we need to address three key 
methodological issues. First, our outcome is extraordinarily rare. Second, our exposure, while 
common, is not randomized, and thus is likely to be confounded by many patient- and practice-
related covariates, especially confounding by practice and by indication.  Third, exposure and 
outcome will both likely be clustered by patient and practice.  We use different methods to 
address these methodological challenges.  To the extent that our results from these various 
methods agree, this supports our results; to the extent that they disagree, they can give us further 
insights into the relationship between antibacterial drug exposure and adverse events.  
 
Methods 
 We conducted a retrospective cohort study using data accessed from THIN in September 
2007.  Data were restricted to practices meeting acceptable standards set by EPIC for research 
data collection.  We identified all adult primary care visits for acute nonspecific respiratory 
infections between January 1, 1985 and December 31, 2006 among all continuously-enrolled 
patients >18 years of age.  Visits were identified based on Read diagnostic codes for acute 
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nonspecific respiratory infections. (Chapter 3, Table 1).  We excluded codes for diagnoses often 
attributed to a focus of bacterial origin for which guidelines recommend antibacterial therapy such 
as streptococcal pharyngitis, otitis media, sinusitis, and pneumonia.  Because data from multiple 
visits within the same illness episode may tend to be highly correlated, visits were grouped if they 
occurred within a two-week period; grouped visits are defined as acute nonspecific respiratory 
infection encounters.  For sensitivity analysis, we eliminated the visit grouping.  
Exposure: Exposure of interest was antibacterial drug prescription within one day of the 
index acute nonspecific respiratory infection visit; antibacterial drugs of interest included oral 
antibacterials typically used for respiratory infections.  We excluded topical, vaginal, 
ophthalmologic, otic, and parenteral antibacterials, and those typically used for tuberculosis, 
fungal and parasitic infections.  The primary exposure window was within 14 days of the index 
visit.  Fourteen days was chosen as the primary exposure of interest as we have demonstrated 
that for most antibacterials commonly used for acute nonspecific respiratory infections, most 

















Outcome: The primary outcome for this study was a severe adverse event within a 14 
day window following the index acute nonspecific respiratory infection encounter, defined as 























diarrhea, hepatic toxicity, hypersensitivity, photo-toxicity, renal toxicity, or seizure (Appendix).  
Hospitalizations were identified using the THIN Source codes suggested by EPIC to detect an 
overnight hospital admission. (Bhullar, H, personal communication March 1, 2007). We previously 
showed that these same THIN hospitalization codes had a good positive predictive value for 
identifying valid overnight hospital admissions for community acquired pneumonia, another acute 
diagnosis (Chapter 4), and that, of the identified hospitalizations, almost all (>96%) were 
identified within a 14-day window after the acute nonspecific respiratory infection index  visit.  
However, if an adverse event occurred within the 14 day window but was recorded late, after the 
14 day window, we would miss the outcome of interest. For this reason, our sensitivity analysis 
extended the window out to 30-days exposures to address how robust our results are to 
misclassification of hospitalization dates.  Additional sensitivity analyses include eliminating the 
visit grouping, and utilizing propensity score analysis, described in more detail below. We explore 
our ability to control for unmeasured variables by performing instrumental variable analysis and a 
case-cohort study, also decribed further below.   
By confining our primary outcome to the more severe adverse events, defined as 
overnight hospital admissions, we minimized misclassification bias due to misidentification of 
outcome.  It is less likely that an adverse event was not recorded in THIN, and thus missed, if it 
resulted in a hospital admission and thus generated at least a hospital discharge report and 
perhaps an office and/or emergency department visit.  It is likely that if a hospitalization was 
recorded, an adverse event actually took place; this assumption was confirmed with our validation 
project.  Thus, using hospitalizations as our primary outcome, we may have missed some 
exposure-associated adverse events, but the adverse events we identified will likely be valid.   
Secondary outcomes included less serious adverse events, events resulting in a primary 
care encounter but not resulting in hospital admission.  We chose to make these secondary 
outcomes, first because of concern that the less severe events might not be recorded in the 
medical record and second, we were focusing our primary analysis on more clinically severe, and 
thus perhaps more clinically relevant, adverse events.  We also included automobile crash 
Chapter 6 
96 
hospital admissions as an additional secondary outcome, as a control outcome. This explored the 
possibility that our antibacterial drug exposure measure was a marker for certain patient 
characteristics which made it more likely a patient would be hospitalized, rather than a marker of 
a causal relationship between our antibacterial drug exposure and the hospitalization outcome.   
Exploratory analyses included modeling each individual adverse event category as a 
separate outcome , and modeling severe adverse event hospital admissions on antibacterial drug 
class specific exposure, focusing on beta-lactams, macrolides, and flouroquinolones, first as 
class-specific antibacterial drug vs. no antibacterial exposure, and second as class-specific 
antibacterial drug vs other antibacterial exposure.  Although we had less power to detect this 
outcome than our primary outcomes, the risk of certain adverse events may vary with exposure to 
specific antibacterial drug class, for example, beta-lactam antibacterials may increase the risk of 
seizures,[17] and macrolides and fluoroquinolones may increase the risk of cardiac 
arrhythmias.[18]  As it is possible that some severe adverse events could result in death without 
recording an overnight hospitalization; to explore the possibility that severe adverse events might 
be missed in this way, we also modeled death as an exploratory outcome.   
Covariates: Covariates included patient age at visit, sex, visit year, and patient co-
morbidity history, with co-morbiditites grouped into the categories shown in Chapter 5, Table 4 
(Lewis, JD,unpublished data).  Considering what clinical data might be relevant from a clinical 
aspect to help predict indication for antibacterial treatment of acute nonspecific respiratory 
infections, we also included alternative summary measures of the intensity of medical care use, 
including the number of THIN recorded co-morbidities,[8] and the number of different classes of 
medications that the patient was prescribed[8, 19] and the number of THIN visits recorded for that 
patient within the year prior to the patient’s index acute nonspecific respiratory infection visit.  
Although it would have been ideal to include them in the analysis, THIN does not include direct 
measures of patients’ socioeconomic, racial and ethnic characteristics. THIN does include other 
variables based on the patient’s post code that were used as proxies of these characteristics; 
these variables include the Townsend score, a five-quintile measure of neighborhood deprivation, 
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and a five-quintile variable describing the proportion of the patient’s neighborhood who define 
themselves as “Black” or “Black British.”   
 Analysis: We first summarized acute nonspecific respiratory infection encounters and 
antibacterial drug exposure, overall and by specific antibacterial class defined by British National 
Formulary (BNF) class, [20] and we summarized the frequency and type of adverse events 
outcomes.   
 As described in Chapter 5, antibacterial drug prescribing was profoundly unbalanced 
between practices, and there was enormous confounding by practice in the relationship between 
severe adverse events and antibacterial drug exposure.  For multivariable analysis, we performed 
fixed effects conditional linear regression using Stata’s xtreg command, described in further detail 
in Chapter 5.  We modeled hospitalization for any severe adverse event, using practice as the 
grouping variable. The primary independent variable was antibacterial drug exposure modeled 
as: any antibacterial exposure vs. no antibacterial exposure.  Covariates included those listed 
above. Model covariates were included using a two-step process.  First, we initially included all 
covariates that were associated with the outcome, conditional on the exposure of interest.  Then, 
we retained each covariate in the final model if removing it caused a change of >=10% in the risk 
difference for antibacterial drug use.  Akaike’s Information Criterion (AIC) was used to help 
assess model fit, and Cuzick’s nonparametric test for trend across ordered groups was used to 
test for trend (Stata’s nptrend). 
 For sensitivity analysis, we eliminated the visit grouping, and examined results at 30 
days, as described above.  In addition, we explored the impact of using a propensity score in the 
regression models.  Because our analysis was conditional on practice, and because we expected 
extremely unbalanced antibacterial drug prescribing by practice (propensity for antibacterial drug 
exposure based on other covariates varied widely between practice), a propensity score was 
calculated separately for each practice, using the same covariates in each practice’s model, as 
described in Chapter 5.  Within each practice, propensity scores were divided into quintiles, and 
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then these quintiles of the propensity score for each practice, across all practices were used in 
the conditional linear regression, replacing their included covariates.   
We also considered less severe adverse events, not resulting in hospital admission.  We 
used the same THIN adverse event diagnosis codes for this analysis, but excluded those cases 
associated with THIN hospital admission codes.   
As mentioned above, we modeled a control outcome, overnight hospital admission for 
automobile crash within 15 days of the acute nonspecific respiratory infection visit, which should 
not be related to antibacterial exposure; if a systematic difference is shown in the risk of 
hospitalization for automobile crashes between antibacterial drug-exposed and –unexposed 
patients, this would not plausibly be an effect of exposure and would be evidence of a hidden bias 
due to unmeasured confounding.[21]   
Because of the concern that some severe adverse events may present with death without 
hospitalization, we also modeled death as exploratory outcomes.   
Additionally, to further explore the influence of unmeasured variables on inter-individual 
confounding by indication, we performed a crossover cohort study.[22]  A crossover cohort study 
eliminates inter-individual differences in indication for receiving antibacterials.[22, 23]  In this 
analysis, patients with adverse event hospitalizations and >1 visit for acute nonspecific 
respiratory infection were included in the study population.  Case time was defined as the 14 days 
following a severe adverse event index acute nonspecific respiratory infection grouped visit.  A 
history of severe adverse event after antibacterial drug use would have been a contraindication 
for future use of this antibacterial drug.  To minimize bias from confounding due to depletion by 
susceptibles, control time was defined as the 14 days following the previous[22] non-index visit; 
control time after the index acute nonspecific respiratory infection visit was not included.  Chi-
square testing was used to calculate the odds ratio comparing adverse event for antibacterial 
drug-exposed vs. unexposed visits for each patient.   
 
Power 
 Primary analysis: Power calculations were performed conservatively, using PS Power and 
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Sample Size Calculations, Version 2.1.30, 2003.[24]  THIN covers 32.6 million person-years,[25] and 
using the 2001-2002 U.S. outpatient visit rate of 1985.7 visits per 1000 adults,[3] predicts an 
estimated 64,733,820 THIN outpatient visits, assuming the U.K. outpatient visit rate is similar to that 
of the U.S.  Approximately 11% of adult outpatient visits are for acute respiratory infections other 
than pneumonia;[3, 26, 27]  assuming a similar rate for the U.K., we estimated a total of 7,120,720 
outpatient acute nonspecific respiratory infection visits covered in THIN.  In the U.S., 61.8% of adults 
diagnosed with acute nonspecific respiratory infection in the outpatient setting are prescribed 
antibacterial medications,[3] and our power calculations conservatively assumed that the U.K. 
antibacterial prescribing rate could be only ½ of the U.S., or 30.9% of acute nonspecific respiratory 
infection visits.  The preliminary study found an adverse event rate of 0.207 serious adverse events 
per 1000 antibacterial drug-prescribing visits.[28]   
 With these assumptions, assuming data are independent, using the U.S. antibacterial 
drug prescribing rate of 61.8%, even if our sample size is half that estimated above, or 3,500,000, 
we would have 95% power to detect a relative risk of 1.20 for a serious adverse event for a 
patient exposed to antibacterials compared with an unexposed patient, or a 20% increased risk 
from antibacterial exposure.  The clustered nature of our data means that data within practices 
are likely to be more similar than data across, or between practices; this imparts variance 
inflation.  With visits clustered by practice, assuming a mean of 10,700 visits per practice, with an 
intracluster correlation coefficient as high as 0.2, we would still have over 95% power to detect 
this difference with this expected sample size. [29]  f the U.K. antibacterial drug prescribing rate 
was only 30.9% of acute nonspecific respiratory infection visits, we would have 90% power to 
detect this same difference (Table 11).  These results indicate that we would have the power to 
detect a clinically significant increased risk of a serious adverse event associated with 
antibacterial drug exposure.  While these relative increases in risks are large, the associated 
absolute increases in risk are small but clinically meaningful, particularly given the limited clinical 




Table 11. Power, Relative Risk of Severe Adverse Event, Exposed vs. Unexposed Visits 
Power, Relative Risk of Severe Adverse Event 
Exposed vs. Unexposed Visits 
 
Power Acute Nonspsecific Respiratory Infection 
Antibacterial Prescription Rate 





.90 0.309 1.20 
 
 Crossover cohort study 
 For the crossover-cohort study, preliminary data show that 136 adults had a severe 
adverse event after >1st acute nonspecific respiratory infection visit. Using the methods of Julious 




Description of the cohort 
Visits 
 Our cohort contained 1,646,229 total visits and 1,531,019 grouped encounters by 
814,283 patients.  The mean number of grouped encounters per patient was 1.9 (median 1, 
range 1 to 88 visits, Chapter 5, Figure 6).  There were 495,129, 164,447, 70,145, 34,373, 18,466 
and 748,479 patients with 1,2,3,4,5, and >5 visits, respectively (Chapter 5, Table 6, Figure 6).  
There were 326 practices included in the cohort. The mean number of grouped visits per practice 
was 4696.4 (median 3232.5, range 24 to 27,190, Chapter 5, Table 7 and Figure 7)   
Antibacterial drugs 
Overall, patients at 65.4% of acute nonspecific respiratory infection visits received 
antibacterial drug prescriptions.  As expected, antibacterial drug prescribing varied widely 
between practices, from a low of 3.1% to a high of 94.7% of grouped visits receiving antibacterial 
prescriptions (Chapter 5, Figure 8).  As described in more detail in Chapter 5, this extreme 
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unbalance of antibacterial drug prescribing across practices provided strong evidence that we 
needed to address any clustering and confounding by practice.   
The most frequent antibacterial drug prescribed was amoxicillin followed by penicillin and 
then erythromycin for 51.2%, 17.0%, and 12.7%, respectively of encounters prescribed 
antibacterial drugs (Table 12).   
 
Table 12. Antibacterial Drugs Prescribed 
Antibacterial Drugs Prescribed 
 


















































































































In general, subjects with visits where antibacterial drugs were prescribed had more pre-
existing health conditions, for most of our co-morbidity measures for example they were older 
(mean age for those receiving antibacterials vs. for those not receiving antibacterials was 47.9 vs. 
44.0 years), had a more frequent history of any co-morbidities (34.9% vs. 30.6%), more different 
types of co-morbidities (mean 0.48 v. 0.41), and more classes of drugs (mean 6.0 v. 4.3) within 
the year prior to the acute nonspecific respiratory infection visit, although the number of primary 
care visits within the previous year was similar between the two exposure groups (Table 13).   
 
Table 13. Characteristics of Patients with Antibacterial Drug-exposed vs.Antibacterial-
unexposed Encounters 











     Median 







  Male (%) 385,712 (38.5) 184,720 (35) 
  Congestive heart failure 26,692 (2.66%) 10,352 (1.96%) 
  Lung disease 195,831 (19.54%) 90,894 (17.18%) 
  Rheumatologic disease 29,607 (2.95%) 14,251 (2.69%) 
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  Cerebrovascular disease 35,224 (3.52%) 16,073 
 (3.04%) 
  Dementia 3,216 (0.32%) 2,425 (0.46%) 
  Diabetes 43,785 (4.37%) 18,682 (3.53%) 
  Weakness 6,436 (0.64%) 2,849 (0.54%) 
  Human Immunodeficiency  
    virus infection 
296 (0.03%) 178 (0.03%) 
  Malignancy 43,816 (4.37%) 18,723 (3.54%) 
  Metastatic malignancy 1,345 (0.13%) 565 (0.11%) 
  Mild liver disease 6,777 (0.68%) 3,052 (0.58%) 
  Moderate-severe liver disease 708 (0.07%) 341 (0.06%) 
  Myocardial infarction 26,192 (2.61%) 9,959 (1.88%) 
  Peptic ulcer disease 35,105 (3.50%) 14,385 (2.72%) 
  Peripheral vascular disease 21,982 (2.19%) 8,963 (1.69%) 
  Renal disease 6,571 (0.66%) 2,982 (0.56%) 
  Any comorbidity 350,078 (34.94%) 161,607 (30.55%) 
  Number of comorbidities 
     Mean 







  Number of different classes of 
drugs used in previous year 
     Mean 









  Number of visits made in 
previous year  
     Mean 











Severe adverse event hospitalizations 
The incidence rate of severe adverse events within 14 days of encounters was 
0.0000771 events per encounter, or 7.71 events per 100,000 encounters, shown in Figures 10 
and 11 and Table 14.  The unadjusted incidence rate was 7.88 per 100,000 encounters with 
















Without antibacterial drugs 
528,969 encounters 
TOTAL 




6 liver toxicity 







5 liver toxicity 








20 liver toxicity 







8 liver toxicity 







Any antibacterial drug exposure vs. no antibacterial drug exposure 
Severe adverse event hospitalization 
Using practice as the cluster variable, the unadjusted conditional fixed-effects within-
practice estimate for the risk difference for severe adverse event for patients exposed vs. those 
unexposed to antibacterial drugs was -0.00000677 (95% c.i. -0.0000383 to +0.0000247); this 
crude result implies that antibacterial drugs decrease the risk of severe adverse events with a risk 
of -0.677 per 100,000 visits.   
 The variables found to be confounders  when considered individually (age as a four-knot 
spline, number of comorbidities, number of different classes of drugs used and the number of 
recorded visits in the previous year, Townsend score, and racial distribution) and centered year 
were used for the initial multivariable model. Variables were eliminated individually, and remained 
out of the model if their elimination resulted in a <10% in the coefficient of interest, the risk of 
severe adverse event.  Ultimately, the final model included age, year, the number of drugs, 
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number of visits, and the Townsend score, with a risk difference of -1.42 per 100,000 visits (95% 
c.i. -4.75 to +1.91, p=0.40) comparing antibacterial drug-exposed vs. unexposed visits, Table 15.  
Sensitivity analysis 
 Eliminating visit grouping: Eliminating visit grouping, results were the same, with a risk 
difference of -1.42 (95% c.i. -4.75 to +1.91, p=0.403) comparing exposed vs. unexposed visits.  
Results for 30 days demonstrated even greater risk reduction for antibacterial drug exposure vs. 
unexposed patients, although still not statistally significant, with a point estimate for the risk 
difference of -3.79 (95% c.i. -8.38 to +0.802, p=0.106) .   
Propensity score analysis: In order to get the propensity score models to successfully 
converge, we needed to dichotomize our continuous predictors of exposure, and we were still not 
able to generate pscores for eleven of the 326 practices (including 90,885 of 1,531,019 visits in 
the cohort) (Chapter 5).  Including encounters from only the 311 practices with propensity scores, 
the risk difference for  severe adverse event was .-1.45 (95% c.i. -4.96 to +2.06, p=0.419) 
comparing exposed vs. unexposed encounters, similar to the risk difference estimate using all of 
the data (Table 15).  We then fitted the same model, substituting categorical propensity score for 
the included covariates. Risk difference for severe adverse event, stratified by propensity score 
category, was -1.87 (-5.43 to +1.68, p=0.301), comparing antibacterial drug-exposed vs. 
unexposed visits, with the point estimate slightly farther from the null, but with overlapping 
confidence intervals compared with the estimate using the model without the propensity score 
(Table 16).  We also examined what happened to the risk difference estimate when the model 
was used for only one propensity score category at a time; there did not appear to be a trend in 








Table 15. Adverse Event Outcomes 
Adverse Event Outcomes 
 Per 100,00 encounters 
All antibacterial drugs, at 14 days, 
grouped encounters 
Risk difference for antibacterial use 
 Point  
Estimate 
95% c.i. p-value 
SEVERE ADVERSE EVENTS    
Model without propensity score    
     Including all encounters -1.42 -4.75 to +1.91 0.403 
     Including only encounters with a 
propensity score 
-1.45 -4.96 to +2.06 0.419 
Model with propensity score    
     All propensity score quintiles -1.87 -5.43 to +1.68 0.301 
     1st propensity score quintile +3.07 3.58 to +9.72 0.365 
     2nd propensity score quintile -4.93 -12.41 to +2.56 0.197 
     3rd propensity score quintile -4.55 -12.42 to +3.32 0.257 
     4th propensity score quintile -0.366 -9.88 to +9.14 0.940 
     5th propensity score quintile -2.56 -11.72 to +6.60 0.584 
Crossover cohort analysis -0.99 -4.15 to +5.61 .66 
LESS SEVERE ADVERSE EVENTS +55.58 +28.00 to +83.18 <0.001 
HOSPITALIZATION FOR MOTOR 
VEHICLE CRASHES 
-0.78 -1.70 to +0.13 0.093 
 
Less severe adverse events 
 For less adverse events that did not result in hospitalization, the risk difference for mild 
adverse event for antibacterial drug-exposed vs. antibacterial-unexposed visits was +55.58 per 
100,000 visits (95% c.i. +28 to +83.18, p<0.001), Table 19, implying a significant increased risk 
for adverse events, rather than the null effect seen for the more severe adverse events (Table 
15).   
 
Control outcome: Hospitalization for motor vehicle crashes 
We modeled a control outcome, hospitalization for motor vehicle crash, which should not 
be related to antibacterial exposure.  Using the multivariable model, the risk difference for 
hospitalization for antibacterial drug-exposed vs. unexposed visits was -0.783 per 100,000 visits 
(95% c.i. -1.7 to +0.131, p=0.093), Table 15.  
 
Crossover cohort study 
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Sixty-one case visits were matched with 173 control visits by the case patients.  All 
control visits occurred prior to the case visit for each patient.  Odds ratio for antibacterial drug-
exposed vs. unexposed visits was 0.87 (95% c.i. 0.44 to  1.76, p=0.66), Table 15.  Using the 
value for risk of severe adverse event for patients with baseline covariates from the conditional 
linear regression results above, this implies a risk difference of - 0.9927, compared with -1.42 
from the conditional linear regression results.  The crossover cohort results were thus closer to 
the null result of no risk difference than the point estimate of the risk difference from the 
conditional linear regression results.     
 
Exploratory Analyses 
Individual adverse event category: 
 Individual adverse event category and all antibacterial drugs 
 Considering individual adverse event categories, risk difference point estimates ranged 
from -1.42 per 100,000 visits up to +0.556 per 100,000 visits but only one, for diarrhea, was 
statistically significant, an unremarkable result considering the multiple comparisons.  (Table 16).   
 
Table 16. Regression Results for Individual Adverse Event Types 
Regression Results for Individual Adverse Event Types 
 Per 100,00 visits 
 Risk difference for antibacterial drug use 
All antibacterial drugs, at 14 
days, grouped encounters 
Point estimate 95% c.i. p-value 
Severe adverse events -1.42 -4.75 to +1.91 0.403 
     Hypersensitivity +0.464 -1.58 to +2.51 0.656 
     Diarrhea -1.25 -2.46 to -.0407 0.043 
     Hepatic toxicity -0.518 -1.49 to +0.452 0.295 
     Renal toxicity +0.820 -0.588 to +2.33 0.254 
     Arrhythmia +0.556 -0.166 to +1.28 0.131 
     Seizure -1,18 -2,55 to +0.189 0.091 
 
Class-specific antibacterial drug exposure 
Class-specific antibacterial drug exposure vs. no antibacterial exposure 
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 When assessing class-specific antibacterial drug exposure vs. no exposure, we were 
faced with sparse data and multiple comparisons (Table 17).  Point estimates of the risk 
difference for severe adverse events for beta lactams and macrolides were negative, and for 
flouroquinolone was positive, but none of these differences were statistically significant.   
Class-specific antibacterial exposure vs. other-antibacterial exposure  
 When assessing class-specific antibacterial drug exposure vs. other antibacterial 
exposure, point estimates of the risk difference for severe adverse events for beta lactams was 
negative, and for macrolides and flouroquinolones was positive, but again, none of these 
estimates were statistically significant (Table 17).   
 
Table 17. Regression Results by Antibacterial Drug Class: Severe Adverse Events 
 Severe Adverse Events Per 100,00 visits 
Grouped encounters Risk difference for antibacterial drug use 
 Point estimate 95% c.i. p-value 
All antibacterial drugs  
     Antibacterial drug use vs. none -1.42 -4.75 to +1.91 0.403 
          Ungrouped -1.42 -4.75 to +1.91 0.403 
Specific antibacterial class vs. none 
Beta‐lactams  -1.70 -5.15 to +1.76 0.335 
Macrolides  -0.10 -6.29 to +6.09 0.975 
Flouroquinolones  +1.43 -16.21 to +19.06 0.874 
     Specific antibacterial class vs. other antibacterial class 
Beta lactams  -1.35 -5.59 to +2.88 0.531 
Macrolides  +2.10 -3.34 to +7.53 0.450 
Flouroquinolones  +10.39 -6.15 to +26.92 0.218 
 
Deaths 
Deaths within 14 days of encounters were rare, with a mean incidence rate of 87.9 per 
100,000 encounters.  The unadjusted rate was 70.66 per 100,000 encounters with antibacterial 
drug exposure and 120.61 deaths per 100,000 acute nonspecific respiratory infection encounters 
without antibacterial exposure.  There were 102 practices with zero death outcomes within 14 
days of grouped visits, and 46, 32, 29, 19, 18, and 80 practices with 1,2,3,4,5, and >5 death 
outcomes, respectively.   
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Using practice as the panel variable, the unadjusted conditional fixed-effects within-
practice estimate for the risk difference for death for patients exposed vs. those unexposed to 
antibacterial drug was -0.0006239 (95% c.i. -0.0007302 to -0.0005175, p<0.001); this unadjusted 
result implies that antibacterial drugs decrease the risk of death by 62.39 per 100,000 visits.     
 The variables found to be confounders when considered individually analysis (age as a 
five-knot spline, number of co-morbidities, and the number of different classes of drugs used) and 
centered year were retained for consideration in the multivariable model.  Adjusting for age and 
the number of comorbidies and different types of drugs used in the previous year, the risk 
difference was -84.26 (95% c.i. -95.00 to -73.53, p<0.001, comparing antibacterial exposed vs. 
unexposed visits (Table 16,18).  Eliminating visit grouping, results were the same, an estimated 
risk difference of -84.26 per 100,000 visits (95% c.i. 95.0 to -73.53, p<0.001).  Results at 30 days, 
similar to adverse event results, were away from the null at -99.70 per 100,000 visits (95% c.i. -
113.93 to -85.47, p<0.001).  In propensity score analysis, risk difference for death, stratified by 
propensity score category, was -92.52 (-104.01 to -81.03, p<0.001), comparing antibacterial 
exposed vs. unexposed visits.   
 
Discussion 
 Antibacterial drug use is very common, and patients sometimes experience severe 
adverse events that are temporally related to taking these medications.  Certain adverse events, 
particularly the conditions included in this study, are often believed to have a causal relationship 
with patients’ antibacterial drug use; most of these associations have been established using 
case reports, but case reports of adverse events do not include an unexposed comparison group, 
and are thus ill-suited for establishing a causal association.   
Approximately half of patients with primary care visits for acute nonspecific respiratory 
tract infections receive treatment with antibacterial drugs.  In this study, we compared the risk of a 
severe adverse event or death for antibacterial exposed vs. unexposed patients who were similar 
otherwise in that they experienced a primary care visit for nonspecific respiratory tract infection.  
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Methods outlined in Chapter 5 were used to model our extremely rare outcome, and help control 
for clustering and confounding by practice and confounding by indication.  In addition, sensitivity 
analyses explored how robust our results were to our primary model assumptions.  We also 
explored some secondary and exploratory outcomes of interest.   
Patients with acute nonspecific respiratory infections treated with antibacterial drugs were 
not at increased risk of severe adverse events, with a point estimate for the risk difference of -
1.42 per 100,000 visits with a confidence interval that included zero. 
The results were robust to eliminating the visit grouping.  Extending the exposure window 
from 14 to 30 days after the index visit moved both the adverse event and death estimates 
somewhat away from the null, most likely from including more events less related to the index 
visit, and more related to patients’ underlying condition, but did not alter the general conclusions.   
Results using a propensity score analysis were slightly farther from the null, in the 
direction of protection against adverse events, although still did not reach statistical significance.  
In theory, the propensity score is well suited to increase our power to show a risk difference, with 
our rare outcome and common exposure,  However, many practices had to be dropped from the 
our propensity score analysis because the propensity score models would not converge, due to 
covariate imbalance.  There is reason to believe that practices with missing propensity scores 
may be different in systematic ways from practices with more covariate balance between 
exposure groups.  Further information was lost when some continuous variables needed to be 
dichotomized to reach propensity score convergence.  For these reasons, the model without the 
propensity score most likely provided less biased estimates than the propensity score model.   
Antibacterial drug class-specific analyses were limited by sparse data and multiple 
comparisons.  When compared to no antibacterial drug use, none of the antibacterial classes 






Considering less severe adverse events, those resulting in a subsequent primary care 
visit within the 14-day exposure window, but not resulting in hospitalization, there was an 
apparent increased risk of less severe events with antibacterial drug exposure of +55.58 per 
100,000 visits.  Given that this effect was not seen with the severe events, it is possible that this 
result is secondary to misclassification, in that minor adverse events after antibacterial exposure 
might be more likely to be reported and recorded than similar events without antibacterial 
exposure, while hospitalizations are more likely to be reported and recorded whether or not the 
patient is on antibacterial drug treatment.  This is the reason we chose the much rarer but more 
specific severe event category for our primary outcome, and our results seem to support this 
choice.  Alternative possibilities are that antibacterial drugs increase the risk of minor but not 
severe adverse events, and/or that our hospital admission outcomes suffer from additional 
misclassification and/or bias compared with the outpatient outcomes.  
If a systematic difference was shown in the risk of a known, control outcome, such as 
hospitalization for automobile crashes, between antibacterial drug-exposed and –unexposed 
patients, this would not plausibly be an effect of exposure and would be evidence of a hidden bias 
due to unmeasured confounding.[21]  In this study, patients with antibacterial drug exposure were 
not more likely than unexposed patients to be hospitalized with a diagnosis of motor vehicle 
crash; this result is expected and reassuring that our methods yielded these expected results.  
The two types of outcomes may not be directly comparable however. Our study did not address 
the issue of disparities in health care access, which might differentially affect different outcomes, 
for example automobile crash outcomes may be more or less likely to be related to patient 
characteristics that could be correlated with access to health care.  This is less likely to be an 
issue in the U.K., with their National Health Service, than in the U.S.  
 The instrumental variable analysis seemed to look somewhat different from results from 
the other models, closer to the null. However, as described in Chapter 5, the IV results really 
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describe between-practice estimates of the risk difference, when our estimate of interest was the 
within-practice risk differences.   
Results from the crossover cohort study further support the null results of the primary 
analysis, in that results are even closer to the null when antibacterial drug-exposed time is 
compared to antibacterial-unexposed time within the same patient; this may reflect a true control 
of some inter- patient confounding by indication.  However crossover cohort methods are less 
suitable for some outcomes, like deaths, where it’s difficult to find suitable control time.  
Crossover cohort methods in this study are somewhat limited by the difficulty of using control time 
sampled after the adverse event, Patient’s comorbidities change with time, (usually they tend to 
get sicker with time), and thus their indication for treatment tends to change with time in a positive 
fashion. Because many studies, like this one, have difficulty making use of control time after the 
case event (most phyisicns would be less likely to prescribe an antibacterial drug if the patient 
has previously had a severe adverse event associated with one. thus, we still have to deal with 
the possibility of within patient confounding by indication; despite having some temporal 
information in our visit date variable, we were probably not completely able to deal with the fact 
that our patients have different indications at different times.  
 
Limitations: 
Misclassification: Limitations of this study include that we were limited by the potential 
inaccuracy of THIN data.  For example, there may have been exposure misclassification 
(antibacterial use with acute nonspecific respiratory infections). Drug prescriptions are generated 
by data entry into the electronic medical record, and primary care general practitioners are 
responsible for most medication prescribing, so capture of drug prescription information in THIN 
is virtually 100%.[30, 31]  However, some antibacterial drugs used to treat patients may be 
missed, for example, telephoned prescriptions not associated with an coded visit, and some more 
recent urgent care visits, would not be included in our data.  Also, we have no data regarding 
whether the prescriptions were filled or ingested.  Our visit grouping classified the encounter as 
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antibacterial drug-exposed if any of the visits within the included two-week window included an 
antibacterial prescription , and thus may have misclassified in favor of antibacterial use, however 
our results were virtually identical with ungrouped analysis.   
We also need to consider outcome misclassification (adverse events after the visit).  As 
the outcome is entered after exposure, it is possible that there will be differential ascertainment of 
outcome based on antibacterial drug exposure, for example, patients exposed to antibacterial 
drugs who experience an adverse event may be more likely to come to medical attention than 
unexposed patients.  Differential ascertainment of outcome may be less likely for our primary 
outcome of severe adverse events resulting in hospitalization than for less severe events, 
however it is possible that adverse events may be more likely to be identified and diagnosed as 
such for patients who are hospitalized.  People who get admitted to the hospital for any reason 
may be more likely than people who do not get admitted to receive an adverse event diagnosis. If 
people who do not receive antibacterial drugs are more likely to be admitted to the hospital, they 
may be more likely to receive a severe adverse event diagnosis; this would have biased our 
results toward the null.   
We addressed the specificity of our hospitalization diagnosis with the validation study 
described in Chapter 4, which supported the validity of our hospitalization outcome, however we 
did not address diagnosis sensitivity; some of our outcome diagnoses may have been missed, 
however there is no reason to suspect that hospitalization diagnoses would be more or less likely 
to be recorded in antibacterial drug-exposed vs. unexposed patients, as discussed above.   
 Confounding: Confounding, especially confounding by indication is another potential 
limitation of this study.  We addressed measured confounders using the methods described 
above; a strong instrumental variable would have been helpful to address unmeasured 
confounders; future studies including validated data on prescriber within practice may be able to 
further address this issue.   
. Generalizability: THIN data come from the U.K., however there is no reason to think that 
individuals in the U.K. have different risks related to antibacterial drug exposure than individuals 
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living elsewhere.  Results from this study are not necessarily be generalizable to patients with 
illnesses other than acute nonspecific respiratory infections, other types of hospitalization 
outcomes than those specifically measured here, or in other very different populations, for 
example, for children.   
In conclusion, case reports of adverse events temporally associated with antibacterial 
drug use have traditionally been used as evidence of a causal relationship between use of that 
drug and the adverse event.  This anecdotal evidence does not provide strong support for a 
causal association, in particular because such analyses lack a control group and do not control 
for confounding by indication, the fact that patients who are more likely to be at baseline risk of 
adverse event are also more likely to be prescribed the medication in question.  This very large 
study included a control group of similar patients without antibacterial drug exposure, and took 
advantage of linked clinical and demographic data to minimize confounding by indication, and 
analytic techniques to minimize confounding by practice.  Patients with acute nonspecific 
respiratory tract infection treated with antibacterial drugs were not at increased risk of severe 
adverse event or death within 14 days of exposure compared with antibacterial-unexposed 
patients.  Adverse event reporting without data on unexposed patients may not reflect a true 
causal relationship between the drug and the adverse event.  While there are other compelling 
reasons to not treat patients with acute nonspecific respiratory infections with antibacterial drugs 
(e.g., drug costs, contribution to emerging drug resistance), the use of antibacterial drugs in these 




















































































Chapter 7. Outcomes II: Potential Benefits of Antibacterial Drug Use: Pneumonia 
hospitalization outcomes after acute nonspecific respiratory infection; assessing the 
influence of antibacterial drug treatment 
Every individual in the U.S. is prescribed a short-term course of systemic antibacterial 
drugs once every three years to almost twice per year, on average, resulting from a visit to an 
ambulatory health care provider.[1-6]  Acute respiratory tract infections account for approximately 
10% of the 6.2 billion annual U.S. outpatient visits.[4]  Approximately half of these diagnoses are 
for acute nonspecific respiratory tract infections.  Unlike conditions with a defined presumed 
bacterial focus, such as pneumonia, bacterial sinusitis, and acute exacerbations of chronic 
bronchitis, for which antibacterial drugs have demonstrated benefit, multiple randomized clinical 
trials have failed to demonstrate a clear benefit from the use of antibacterial drugs to treat acute 
nonspecific respiratory infections, such as nasopharyngitis, acute bronchitis, and acute rhinitis, 
usually of viral etiology.[4, 7]   
 In Chapter 6, we showed that serious risks related to antibacterial drug use for 
acute nonspecific respiratory infections are very low; in this chapter, we explore potential benefits 
of antibacterial drug use.  Numerous practice guidelines[8-12] recommend against antibacterial 
drug treatment of acute nonspecific respiratory infections, but antibacterials are often prescribed; 
adults at about half of U.S. office visits for acute nonspecific respiratory infections receive 
antibacterial prescriptions.[3, 4, 13]  Many of the randomized clinical trials that failed to measure a 
significant benefit to antibacterial drugs for acute nonspecific respiratory infections were relatively 
small and potentially underpowered to detect small but clinically significant benefits. [7, 9, 14, 15] 
These benefits could include faster disease resolution or prevention of progression to more 
serious bacterial infections.  Given the large number of acute nonspecific respiratory infections 
per year, even a small relative benefit might translate into a large public health effect.   
The objective of this study is to compare the risk of a hospitalization for pneumonia 
between THIN patients prescribed antibacterial drugs vs. the risk for those not prescribed 
antibacterial drugs, conditional on a primary care visit for acute nonspecific respiratory infection.  
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Our hypothesis is that patients with acute nonspecific respiratory infections with exposure to 
antibacterial drugs have a decreased risk of pneumonia hospitalizations compared with 
antibacterial-unexposed patients with acute nonspecific respiratory infection.  We used methods 
discussed in Chapters 5 and 6 to address analytic issues related to rare outcomes, clustering and 
confounding by practice, and confounding by indication.   
 
Methods 
  The data source for this retrospective cohort study was again the September 2007 
dataset from The Health Improvement Network (THIN).  We used the same cohort of adult THIN 
primary care visits for acute nonspecific respiratory infection used for the study of adverse events 
described in Chapter 6.  Because data from multiple visits within the same illness episode may 
tend to be highly correlated, visits were again grouped if they occurred within a two-week period; 
grouped visits were defined as encounters.  For sensitivity analysis, we eliminated the visit 
grouping.  
Exposure: Exposure of interest was antibacterial drug prescription within one day of the 
index visit for acute nonspecific respiratory infection; antibacterials of interest included oral 
antibacterials typically used for respiratory infections.  We excluded topical, vaginal, 
ophthalmologic, otic, and parenteral antibacterials, and those typically used for tuberculosis, 
fungal and parasitic infections.  Primary exposure window was within 14 days of the index 
encounter as most antibacterial exposure associated with treatment of acute nonspecific 
respiratory infection is completed within 15 days (Figure 13).[16]    
 Outcome: The primary outcome for this study was hospitalization for pneumonia 
within a 0-15 day window following the index encounter for acute nonspecific respiratory infection, 
defined using Read diagnostic codes for pneumonia (Table 21) and THIN hospitalization Source 
codes (Bhullar, H, personal communication March 1, 2007). We previously showed that these 
same THIN pneumonia and hospitalization codes had a good positive predictive value for 
identifying valid hospitalizations for pneumonia, (Chapter 4), and that, of the identified 
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hospitalizations, almost all (>96%) were identified within two weeks after the acute index visit.  In 
sensitivity analysis , we extended the window out to 30-days exposures to address how robust 
our results are to misclassification of hospitalization dates.  We also modeled admission between 
2 and 15 days after the index encounter, to see how robust our results were to eliminating 
relatively immediate hospitalizations occurring within one day of the visit for acute nonspecific 
respiratory infection, which may be more related to the patient’s original condition than to the 
physician’s antibacterial drug treatment decision.  Also, for comparison, we modeled hospital 
admissions in general for all diagnoses other than the severe adverse event diagnoses 
considered in Chapter 6.    
 


































































Covariates: Covariates included patient age at visit, sex, and visit year.  Although it would 
have been ideal to include them in the analysis, THIN does not include direct measures of 
patients’ socioeconomic, racial and ethnic characteristics. THIN does include other variables 
based on the patient’s post code that were used as proxies of these characteristics; these 
variables include the Townsend score, a five-quintile measure of neighborhood deprivation, and a 
five-quintile variable describing the proportion of the patient’s neighborhood who define 
themselves as “Black” or “Black British.”.  As above for the severe adverse event outcome 
(Chapter 6) .considering what clinical data might be relevant from a clinical aspect to help predict 
indication for antibacterial treatment of acute nonspecific respiratory infections, we also included 
alternative summary measures of the intensity of medical care use, including including the 
number of THIN recorded co-morbidities, with co-morbiditites grouped into the categories shown 
in Chapter 5, Table 4 (Lewis, JD,unpublished data),[17] and the number of different classes of 
medications that the patient was prescribed[17, 18] and the number of THIN visits recorded for 
that patient within the year prior to the patient’s index encounter.   
 Analysis: We calculated descriptive statistics for exposures and outcomes separately.  
For the primary multivariable analysis our previous studies, above, showed that antibacterial drug 
prescribing was profoundly unbalanced between practices, and that there was enormous 
confounding by practice in the relationship between our rare outcome and antibacterial exposure, 
that practice level covariable data were limited, and covariable adjustment was unlikely to be able 
to adjust for this confounding by practice.  Thus, to obtain unbiased estimates for our outcome of 
interest, hospitalization for any pneumonia diagnosis, our models needed to condition on practice, 
and our models used practice as the grouping variable; Confounding by patient was more likely to 
be well-controlled using available patient-level covariates.  For consistency and comparison with 
the other studies described above, and to control for clustering and confounding by practice, and 
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to provide within-practice risk difference estimates, we performed fixed effects conditional linear 
regression using Stata’s xtreg function, described in further detail in Chapter 5.   
Model covariates were included using the two-step process described in Chapter 6.  First, 
we initially included all covariates that were associated with the outcome, conditional on the 
exposure of interest.  Then, we retained each covariate in the final model if removing it caused a 
change of >=10% in the risk difference for antibacterial drug use.   
 For sensitivity analysis, we eliminated the visit grouping, and examined results at 
30 days, as described above.  As described above, we also modeled admission between 2 and 
15 days after the index encounter for acute nonspecific respiratory infection, to see how robust 
our results were to eliminating relatively early hospitalizations within one day of the encounter.  
We also explore the possibility that bronchitis encounters might behave differently than 
acute nonspecific respiratory infections with comparatively more upper respiratory symptoms, 
modeling pneumonia hospitalization outcomes in two additional ways, first eliminating encounters 
with a bronchitis acute nonspecific respiratory infection diagnosis, and second, including only 
encounters with a bronchitis diagnosis.   
Power 
Power calculations were performed conservatively, using Stata version 10.1, StataCorp LP.  As in 
Chapter 6, we estimated a cohort of 3.5 million ARI visits  In the U.S., 61.8% of adults diagnosed 
with acute nonspecific respiratory infection in the outpatient setting are prescribed antibacterial 
drugs,[3] and our power calculations conservatively assumed that the U.K. antibacterial prescribing 
rate could be only ½ of the U.S., or 30.9% of index encounters.  
 With these assumptions, with visits clustered by practice, assuming a mean of 10,700 
visits per practice, with an intracluster correlation coefficient (ICC) of 0.15, using the U.S. 
antibacterial drug prescribing rate, a conservative alpha of 0.025, allowing for covariate 
adjustment, and a baseline pneumonia rate without antibacterials of 0.017, or 17 in 1000 visits, 
we would have 90% power to detect a risk difference of 0.0017, or a relative risk of 0.90 
comparing antibacterial drug exposed vs. exposed visits, and we would have 80% power to 
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detect this risk difference with a ICC as high as 0.2.  With only half the U.S. antibacterial drug 
prescribing rate for ARIs, or 30.9%, we would have 90% power to detect this risk difference with 
an ICC of 0.15, and 80% power to detect this risk difference with an ICC as high as 0.20.  A study 
by Petersen et.al. showed that the risk of an outpatient consultation for ‘chest infection’ during the 
month after an outpatient consultation for upper respiratory infection was 17 per 1000 in those not 
treated with antibacterial drugs and 11 per 1000 in those treated with antibacterials, giving a risk 
difference of 6 in 1000 visits, or a 35% decrease in risk.[19]  These results indicate that we would 
have the power to detect any expected, and certainly any clinically significant change in 
pneumonia risk associated with antibacterial drug exposure.   
 
Results 
Description of the cohort 
Visits 
 The cohort was described in greater detail in Chapter 6; it contained 1,646,229 total visits 
and 1,531,019 grouped acute nonspecific respiratory infection encounters by 814283 patients in 
326 practices.  361,553 of these encounters were for bronchitis diagnoses.   
Antibacterial drugs 
Overall, patients at 65.4% of encounters for acute nonspecific respiratory infections 
received antibacterial drug prescriptions.  As expected, antibacterial drug prescribing varied 
widely between practices, from a low of 3.1% to a high of 94.7% of grouped visits receiving 
antibacterial prescriptions (Chapter 5, Figure 8).  As described in more detail in Chapters 5 and 6, 
this extreme unbalance of antibacterial drug prescribing across practices provided strong 
evidence that analytic methods needed to adjust for clustering and confounding by practice.   
For the 361,553 encounters with bronchitis acute nonspecific respiratory infection 




In general, as described in Chapter 6, subjects with encounters where antibacterial drugs 
were prescribed generally had more pre-existing health conditions (Table 12).   
Pneumonia Outcomes 
 There were 296 pneumonia hospitalizations within 15 days of encounters for 
acute nonspecific respiratory infections, 180 in patients who received antibacterial drugs and 116 
in patients without antibacterial exposure.  The unadjusted mean incidence rate of pneumonia 
hospitalization was 0.0001933, or 19.33 per 100,000 encounters; 21.93 in patients without 
antibacterial drug exposure, and 17.96 in patients with antibacterial exposure, giving a crude risk 
difference of 3.97 per 100,000 encounters and relative risk of 0.82.  There were 211 practices 
with zero pneumonia hospitalizations within 15 days of index encounters for acute nonspecific 
respiratory infections.   
Using conditional fixed effects linear regression, with practice as the grouping variable, 
the unadjusted within-practice risk difference was a protective effect of antibacterial drug use of -
4.53 per 100,000 encounters for antibacterial exposed vs. unexposed encounters.  The final 
model adjusted for age, year, the number of comorbidities and, and the number of different 
classes of drugs used by the patient within the year prior to the index ARI encounter; there was a 
risk difference of -8.16 per 100,000 encounters (-13.24 to -3.08, p=0.002), comparing 
antibacterial-exposed to antibacterial unexposed encounters.    
 Results from ungrouped analysis were unchanged.  There were 396 pneumonia 
hospitalizations at 30 days after the index encounter for acute nonspecific respiratory infection, 
248 after receiving antibacterial drugs and 148 without antibacterials.  Using the conditional fixed 
effects linear regression model, adjusted for the same covariates, age, year, number of 
comorbidities and number of drugs used in the previous year, the protective effect of antibacterial 
drug use was 14.6% farther from the null, with a risk difference of -9.35 per 100,000 encounters 
for antibacterial exposed vs. unexposed encounters (95% c.i. -15.22 to -3.47, p=0.002).   
Chapter 7 
126 
 Results with the 2-15 day window yielded a risk difference of -4.38 pneumonia 
hospitalizations per 100,000 visits (-9.08 to +0.331, p=0.068), comparing antibiotic exposed vs. 
unexposed encounters 
 Eliminating the 361,553 patients with bronchitis, the risk difference for antibacterial drug-
exposed vs. unexposed encounters was farther away from the null, at -9.01 per 100,000 
encounters (-13.43 to -4.58, p<0.001).  Considering only the 361,553 bronchitis encounters, the 
within-practice risk difference for pneumonia admission at 15 days was -37.26 per 100,000 
encounters (-59.71 to -14.81 per 100,000 encounters, p=0.001).  
 Hospitalization for other diagnoses: 
We also modeled hospitalizations in general for all diagnoses, to consider outcomes not 
thought to be related to antibacterial drugs.  The risk difference for hospitalization with any 
diagnosis other than the previously-described severe adverse events (hypersensitivity, diarrhea, 
hepatic toxicity, renal toxicity, arrhythmia, or seizure), describing antibacterial-exposed vs. –
unexposed encounters, was -202 per 100,000 visits (-227 to -176, p<0.001) 
Discussion 
 Antibacterial drugs are often prescribed for acute nonspecific respiratory infections, over 
half of patients at U.S. visits for acute nonspecific respiratory infections receive antibacterial drug 
prescriptions,[3] despite numerous practice guidelines[9-12] and public health campaigns[20-22] 
urging otherwise.  Individual decisions regarding antibacterial prescribing are made, not at the 
public policy level, but at the level of each individual physician-patient relationship, where patient-
level risk/benefit considerations are likely to take precedence over societal considerations.[23]   
By limiting our comparison of pneumonia hospitalizations to patients with acute 
nonspecific respiratory infection visits, we simulated a randomized clinical trial by promoting 
comparability between exposed and unexposed patients.  We addressed remaining confounding 
by practice, and confounding by indication with the analytic techniques explored in Chapter 6.   
We found that the crude risk of pneumonia hospitalization after a visit for acute 
nonspecific respiratory infection was small, at 19.33 per 100,000 visits.  The adjusted within-
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practice risk difference, comparing antibacterial exposed vs. unexposed visits of  -4.53 per 
100,000 visits was of larger magnitude than that for avoiding severe adverse events( -1.42 per 
100,000 visits, p=0.40). This corresponds to a number needed to treat of 22,075 to prevent one 
hospital admission for community acquired pneumonia  Results were robust to eliminating our 
visit grouping and to extending the window of exposure.  The risk difference was attenuated 
toward the null when not considering pneumonia hospitalizations during the first day after the 
acute nonspecific respiratory infection encounter.  This could potentially reflect that antibacterial 
drugs would have their greatest effect on the acute exacerbation of a rapidly evolving bacterial 
illness.   
Although practice guidelines recommend that antibacterial drugs not be prescribed for 
both acute nonspecific upper respiratory infections,[7, 9, 10, 24, 25] and bronchitis illnesses,[26] 
some clinicians may treat patients with predominantly upper respiratory symptoms differently than 
patients with predominant cough symptoms.  The similar findings when bronchitis visits were 
eliminated was reassuring.  The protective effect of antibacterial drugs for patients with bronchitis 
diagnoses was further from the null; this deserves further study.   
Patients given antibacterial drugs were at significantly lower risk of being hospitalized 
with any other diagnosis.  Speculating on the reasons for this unexpected result, confounding by 
indication does not adequately explain it, unless patients given antibacterials were likely to be 
healthier such that antibacterials were selectively given to healthier patients and selectively 
withheld from patients with more baseline health problems, which doesn’t make clinical sense.  It 
is possible that there is an underlying reason for this result other than bias; for example 
antibacterial drugs could be protective due to their anti-inflammatory effect, or their effect on 
bacterial colonization.  Further studies are needed to explore the reasons behind this outcome.   
Ecologic studies from the U.S. and the U.K. have examined the relationship between 
antibacterial drug use and hospital admissions.  Majeed et. al. used U.K. National Health Service 
primary care prescribing data and hospital admission data to show that, between 1996 and 2002, 
the overall antibacterial drug prescribing rate decreased by 23%, while hospital admissions for 
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respiratory tract infections increased by 15%.[27]  Mainous et. al. used U.S. population-based 
survey data to conclude that trends in decreasing antibacterial drug prescribing for acute 
bronchitis and cough illnesses between 1996 and 2003 were associated with increasing 
hospitalizations for respiratory infections during that same time period.[28]  Petersen 
et.al.,performed a cohort study more similar to ours, using another U.K. primary care electronic 
medical record database, the General Practice Research Database (GPRD) to look at 
hospitalization for pneumonia within one month of outpatient treatment for “upper respiratory tract 
infection” and “chest infection.”[19]   They found an odds ratiofor “chest infection” in the month 
after a visit for upper respiratory infection of 0.64 for patients treated vs. those untreated with 
antibacterial drugs.  They found that the risk of pneumonia within one month of chest infection 
was high, and substantially reduced by initial antibacterial drug treatment, with odds ratios 
comparing treated to untreated visits ranging from 0.22 to 0.35, depending on patient age.  
However, bronchitis codes were included among the codes used to identify “chest infections”, and 
“bronchopneumonia” codes were included among codes used to identify pneumonia outcomes, 
and hospitalization status was not specified, so it is difficult to directly compare their results to 
those of our study.  A key issue relates to misclassification of diagnosis at the initial visit; if early 
bacterial pneumonia is misclassified as chest infection or bronchitis, the absence of antibacterial 
drug treatment is more likely to be associated with failure to improve and an increased risk of 
hospitalization for pneumonia.   
Limitations: 
Misclassification: Limitations of this study are similar to those in Chapter 6, and include 
that we were limited by the potential inaccuracy of THIN data.  For example, there may have 
been exposure misclassification (antibacterial use with acute nonspecific respiratory infections). 
Drug prescriptions are generated by data entry into the electronic medical record, and primary 
care general practitioners are responsible for most medication prescribing, so capture of drug 
prescription information in THIN is virtually 100%.[29, 30]  However, some antibacterial drugs 
used to treat patients may be missed, for example, telephoned prescriptions not associated with 
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an coded visit, and some more recent urgent care visits, would not be included in our data.  Also, 
we have no data regarding whether the prescriptions were filled or ingested.  As with the previous 
study, our visit grouping classified the encounter as antibacterial drug-exposed if any of the visits 
within the included two-week window included an antibacterial prescription; this may have 
misclassified in favor of antibacterial use, and thus may have caused differential misclassification 
of exposure, however our results were virtually identical with ungrouped analysis.  We also need 
to consider outcome misclassification (adverse events after the visit), however we demonstrated 
in Chapter 4 that pneumonia and hospitalization codes had good specificity for identifying 
pneumonia hospitalizations in THIN.  Even so, there could have been differential ascertainment of 
outcome such that pneumonias may have been more likely to be identified and diagnosed as 
such for patients who are hospitalized; and our finding that patients have increased risk of 
admission for any diagnosis after antibacterial use for acute nonspecific respiratory infections is 
pertinent here, however this should not have been related to antibacterial drug exposure and 
would have tended to bias our results toward the null.  However, if the decisison to admit for 
pneumonia treatment was more likely if the patient had not been previously prescribed antibiotics, 
this could have biased our results away from the null. From a clinical standpoint, it might be just 
as likely that a history of previously not receiving antibiotics would have instead triggered an 
outpatient antibiotic prescription instead of a hospital admission.   
Another relevant area of potential misclassification is that of visit diagnosis 
misclassification.  It is unclear why physicians code for nonspecific respiratory illnesses despite 
their decision to treat with antibacterial drugs. Physicians seem to persistently prescribe 
antibacterials while coding for nonspecific acute respiratory infection diagnoses (nasopharyngitis, 
acute bronchitis, acute rhinitis), supporting the apparent purposeful classification of these 
illnesses as nonspecific vs. coding instead for diagnoses implying a focal bacterial source, such 
as acute sinusitis, pneumonia, etc. which would better support their decision for antibacterial drug 
treatment.. However, perhaps some of the THIN coded acute nonspecific respiratory tract 
infections were really illnesses with an apparent bacterial focus.  To the extent that this 
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misclassification was non-differential, it would have biased our results toward the null. If 
misclassification was differential, if conditions coded as acute nonspecific bacterial infections with 
bacterial focus were more likely to be prescribed antibacterial drugs than similarly-coded illnesses 
without a bacterial focus, this would have biased our results toward the null, in that patients given 
antibacterial drugs may have been more likely, and certainly not less likely, to end up hospitalized 
with bacterial illness.  It would be less plausible that patients with an apparent bacterial focus 
would be less likely to be prescribed antibacterial drugs than patients without a bacterial focus.   
Confounding: Similar to Chapter 6, confounding, especially confounding by indication is 
another potential limitation of this study.  We addressed measured confounders using the 
methods described above.; If patients prescribed antibacterial drugs were sicker, as indicated by 
unmeasured counfounders not included in this study but considered by treating physicians, the 
sicker patients receiving antibacterial drugs would have been more likely to experience 
subsequent pneumonia hospitalizations, the opposite result to that found in our study..A strong 
instrumental variable would have been helpful to address unmeasured confounders; future 
studies including validated data on prescriber within practice may be able to further address this 
issue.  
. Generalizability: THIN data come from the U.K., however there is no reason to think that 
individuals in the U.K. have different risks related to antibacterial drug exposure than individuals 
living elsewhere.  Results from this study are not necessarily be generalizable to patients with 
illnesses other than acute nonspecific respiratory infections, other types of hospitalization 
outcomes than those specifically measured here, or in other very different populations, for 
example, for children.   
In conclusion, patients with acute nonspecific respiratory infections with exposure to 
antibacterial drugs do seem to have a small decreased risk of pneumonia hospitalizations 
compared with antibacterial-unexposed patients with acute nonspecific respiratory infections.  At 
the societal level, we are very interested in eliminating unnecessary antibacterial drug prescribing 
to help slow the spread of antibacterial resistance, and the need to treat 22,000 patients with 
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antibiotics to avoid one hospital admission might seem excessive.  At the level of the physician-
patient encounter, we are most interested in providing the treatment that will best balance 
benefits and risks for that particular patient; the apparent best decision at the patient level is not 
always the ideal decision at the societal level.  Even with a very small likelihood of patient benefit 
from antibacterial drug use, given how common acute nonspecific respiratory infections and 
antibacterial drug treatment are in our society, this dilemma creates an enormous challenge.  One 
solution is to create more practice guidelines, and continue to educate physicians and the public 
regarding more responsible antibacterial drug use, from a societal perspective. Another solution, 
not mutually exclusive, is to continue to develop win-win solutions, so the interests of the 
individual patient and society can be served together.[31]  For example, improvement of point of 
service rapid diagnostic techniques and biochemical markers of disease severity[32] can help us 
target antibacterial drugs to those patients most likely to benefit   These services are quite costly, 
however scaling up their use would decrease marginal costs considerably, and, from a societal 
standpoint, this investment in decreasing antibacterial drug use may be considered cost effective. 

























































































Chapter 8. Conclusions/ Future Directions 
 To help slow the development of resistance to antibacterial drug, physicians are urged to 
decrease unnecessary antibacterial use, but their patients are increasingly elderly and vulnerable, 
making treatment decisions seem more complex than addressed by current treatment guidelines.  
Antibacterial drug prescribing decisions are made within the context of the physician-patient 
encounter, where the perceived benefit/risk ratio for that patient’s present condition is likely to 
take top priority over other competing interests.  It is important to have a comprehensive 
understanding of the pertinent patient-specific benefits and risks related to this class of 
medication to which the U.S. public has virtually universal exposure.  The move toward 
increasingly more personalized medicine calls for a more sophisticated understanding of how to 
use patient- and environmental characteristics to help target antibacterial drug treatment to those 
most likely to benefit.   
 Most information on adverse events associated with antibacterial drug use come from 
spontaneous reports, which suffer from under- and to a lesser extent, over-reporting of events. . 
Without an unexposed control group, it is impossible to know the real risks for treated relative to 
untreated patients, however large prospective randomized studies are not feasible for every 
research question.  Large observational electronic medical record databases contain longitudinal 
data regarding drug utilization from a real-world setting, linked to covariates and outcomes.  
Improving methods to utilize these rich but complex data might help us learn how to better 
address antibacterial drug misuse and overuse at the individual level.   
We used a subset of the entire THIN cohort with an office visit for acute nonspecific 
respiratory infection, to consider antibacterial drug prescribing for acute nonspecific respiratory 
infections and compare outcomes of antibacterial-exposed and antibacterial-unexposed patients.   
 We found that antibacterial drug prescribing for acute nonspecific respiratory infections 
decreased over the study period in the U.K., but, in contrast to antibacterial drug use in the U.S., 
broad spectrum antibacterial prescribing remained quite low, and even most recently, appeared 
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to be decreasing.  More data are needed regarding whether decreasing use may be affecting 
patient outcomes and trends in antimicrobial resistance. 
We found that THIN hospitalization codes performed well in identifying the timing of 
hospitalization events of interest.  This work supports observational THIN studies regarding 
additional medication use outcomes, especially outcomes related to acute conditions and acute 
exposures to antibacterial drugs as well as other medications.   
By limiting our comparison of outcomes to antibacterial drug exposed vs. unexposed 
patients with visits for acute nonspecific respiratory infections, we promoted comparability 
between exposed and unexposed patients in the cohort.  To further control for confounding by 
indication and confounding by practice, we explored methods to assure that the antibacterial -
exposed and -unexposed groups were as comparable as possible.  The rarity of our outcome 
presented an additional analytic challenge.   
We showed that conditional fixed effects linear regression provided stable estimates of 
common exposure treatment effects on rare outcomes.  Results using these models were quite 
similar to results obtained using more traditional methods for binary outcomes, but could utilize all 
available information, even from groups with zero events.  However, comparing the risk of very rare 
events between quite unbalanced groups presents real challenges to power, even with very large 
datasets.  Additionally, if power estimations for observational studies of rare events ignore potential 
baseline variability between groups, and potential confounding covariates, results could be quite 
biased and power estimates may be grossly inflated.   
In our cohort, patients with acute nonspecific respiratory tract infections treated with 
antibacterial drug were not at increased risk of severe adverse events compared to antibacterial-
untreated patients.  It is clear that adverse event reporting without data on unexposed patients 
may not reflect a true causal relationship between the drug and the adverse event.   
Patients with acute nonspecific respiratory infectionswith exposure to antibacterials had a 
small decreased risk of pneumonia hospitalizations compared with antibacterial drug-unexposed 
patients with acute nonspecific respiratory infections.  At the societal level, we are very interested 
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in eliminating unnecessary antibacterial drug prescribing to help slow the spread of antibacterial 
resistance.  At the level of the physician-patient encounter, we are most interested in providing 
the treatment that will best balance benefits and risks for that particular patient; the apparent best 
decision at the patient level is not always the ideal decision at the societal level.  Even with a very 
small likelihood of patient benefit from antibacterial drug use, given how common acute 
nonspecific respiratory infections and antibacterial drug treatment are in our society, balancing 
very small potential risks of benefit from antibacterial drug treatment of acute nonspecific 
respiratory infections vs. societal benefits of reducing overall antibacterial drug use creates 
persistent tension.  Win-win solutions include expanding the use of influenza vaccination, and 
improving point of service rapid diagnostic testing and biochemical markers of disease severity[1] 
to help us target antibacterial drugs to those patients most likely to benefit.    
Our work supports future observational studies regarding additional medication use 
outcomes, especially rare outcomes related to acute conditions and acute exposures to 
antibacterial drugs as well as other medications.  Improving methods for utilizing observational 
data will help us learn how to use the rich and growing electronic medical record data to their full 











Adverse Event Read Codes 
THIN Read Code Description 
Hypersensitivity 
Dermatitis allergic 
Skin allergic reaction 
Dermatitis nummular 
Erythema multiforme exudativum 
Syndrome Stevens-Johnson 
Toxic epidermal necrolysis 
Acne cachecticorum (Hebra) 
Oedema angioneurotic  
Urticaria giant 







Reaction anaphylactic drug 
Erythema due medicine ingested 
Adverse reaction drug ingested 
Allergy drug by mouth 
Shock reaction anaphylactic 
Medical care adverse effects 





Diarrheoea cause not determined 
Bloody diarrhoea 
Hepatic toxicity 
Hepatic function abnormal 
Liver enzymes abnormal 
Appendix 
138 
Liver function test abnormal 
Necrosis massive hepatic acute 
Acute hepatitis 





Toxic hepatitis due drug sensitivity 
Jaudice cholestatic 







Glomerulonephitis antiglomerular basement membrane 
Nephritis glomerulonephritis 







Rapidly progressive glomerulonephritis 
Necrosis kidney acute tubular 
Renal failure 
Renal medullary necrosis 
Renal papillary necrosis 
















Ventricular tachycardia paroxysmal 
Premature heartbeats 
Premature contractions heart 
Premature beats junctional 
Supraventricular ectopic beats 
Seizure 
Epilepsy nonconvulsive generalized 
Petit mal 











ENT drug side effect 
Rep.presc. drug side effect 
Dr stopped drugs - side effect 
Drug declined by patient - side effects 
Drug side effect - acceptable to patient 
Adverse drug reaction notif 





Upper respiratory tract hypersensitivity reaction NOS 
Drug-induced interstitial lung disorders 
Acute drug-induced interstitial lung disorders 
Anaphylactoid glomerulonephritis 
Ingestion dermatitis due to drugs 
Generalized skin eruption due to drugs and medicaments 
Localized skin eruption due to drugs and medicaments 
Drug-induced erythroderma 
Drug-induced pemphigus 
Lichenoid drug reaction 
Drug-induced androgenic alopecia 
Drug induced urticaria 
Drug-induced systemic lupus erythematosus 
Systemic sclerosis induced by drugs and chemicals 
Arthropathy due to hypersensitivity reaction 
Newborn drug reaction and intoxication 
Newborn drug reaction or intoxication NOS 
Late effect of poison drug/medicament/biological substance 
Drug poisoning 
Overdose of drug 
Poisoning by drug and biological substances 
ENT drug poisoning 
Ear nose and throat drug poisoning NEC 
Other and unspecified drug and medicament poisoning 
Other drug and medicament poisoning OS 
Other drug and medicament poisoning NOS 
Drug and medicament poisoning NOS 
Drug medicament or biological substance poisoning NOS 
Adverse drug reaction NOS 
Drug idiosyncrasy NOS 
Allergic reaction 
Unspecified adverse effect of drug or medicament 
Accidental poisoning by drugs medicines and biologicals 
Accidental poisoning by other drugs 
Accidental poisoning by other drugs OS 
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Accidental poisoning by other drugs NOS 
Accidental poisoning by unspecified drugs 
Accidental poisoning by drugs NOS 
Adverse reaction to antibiotics 
Adverse reaction to natural penicillins 
Adverse reaction to cloxacillin 
Adverse reaction to flucloxacillin 
Adverse reaction to amoxycillin 
Adverse reaction to amoxicillin 
Adverse reaction to ampicillin 
Adverse reaction to bacampicillin 
Adverse reaction to ciclacillin 
Adverse reaction to mezlocillin 
Adverse reaction to pivampicillin 
Adverse reaction to talampicillin 
Adverse reaction to azlocillin 
Adverse reaction to carbenicillin 
Adverse reaction to carfecillin sodium 
Adverse reaction to piperacillin 
Adverse reaction to ticarcillin 
Adverse reaction to mecillinam 
Adverse reaction to pivmecillinam 
Adverse reaction to penicillin NOS 
Adverse reaction to chloramphenicol group 
Adverse reaction to thiamphenicol 
Adverse reaction to chloramphenicol group NOS 
Adverse reaction to erythromycin and other macrolides 
Adverse reaction to erythromycin 
Adverse reaction to oleandomycin 
Adverse reaction to spiramycin 
Adverse reaction to macrolide NOS 
Adverse reaction to tetracycline group 
Adverse reaction to tetracycline 
Adverse reaction to chlortetracycline hydrochloride 
Adverse reaction to clomocycline sodium 
Adverse reaction to demeclocycline hydrochloride 
Appendix 
142 
Adverse reaction to doxycycline 
Adverse reaction to lymecycline 
Adverse reaction to minocycline 
Adverse reaction to oxytetracycline 
Adverse reaction to tetracycline NOS 
Adverse reaction to cefaclor 
Adverse reaction to cefadroxil 
Adverse reaction to cefotaxime 
Adverse reaction to cefoxitin 
Adverse reaction to cefsulodin sodium 
Adverse reaction to ceftazidime 
Adverse reaction to ceftizoxime 
Adverse reaction to cephalexin 
Adverse reaction to cefalexin 
Adverse reaction to cephalothin 
Adverse reaction to cephamandole 
Adverse reaction to cephazolin 
Adverse reaction to cefazolin 
Adverse reaction to cephradine 
Adverse reaction to cefradine 
Adverse reaction to cephalosporin NOS 
Adverse reaction to other antibiotics 
Adverse reaction to clindamycin 
Adverse reaction to lincomycin 
Adverse reaction to colistin 
Adverse reaction to sodium fusidate 
Adverse reaction to polymyxin B sulphate 
Adverse reaction to vancomycin 
Adverse reaction to trimethoprim 
Adverse reaction to other antibiotics NOS 
Adverse reaction to antibiotic NOS 
Adverse reaction to other anti-infectives 
Adverse reaction to sulphadiazine 
Adverse reaction to sulfadiazine 
Adverse reaction to sulphadimidine 
Adverse reaction to sulfadimidine 
Appendix 
143 
Adverse reaction to sulphaguanidine 
Adverse reaction to sulphamethoxazole 
Adverse reaction to sulfamethoxazole 
Adverse reaction to sulphafurazole 
Adverse reaction to sulphaurea 
Adverse reaction to sulphonamide NOS 
Adverse reaction to ciprofloxacin 
Adverse reaction to anti-infective NOS 
Adverse reaction to primarily systemic agents 
Adverse reaction to systemic agent NOS 
Adverse reaction to anti-common cold drugs 
Adverse reaction to other respiratory system drugs 
Adverse reaction smooth/skeletal+respiratory system drug NOS 
Adverse reaction to skin mucous membrane eye ENT dental 
drug 
Adverse reaction to anti-infectives and other ENT drugs 
Adverse reaction to other skin eye ENT and dental drugs 
Adverse reaction to skin eye ENT and dental drugs NOS 
Adverse reaction to other drugs and medicines 
Adverse reaction to other drugs and medicines 
Adverse reaction to other drug or medicine NOS 
Adverse reaction to drug or medicinal substance NOS 
Adverse reaction to drug NOS 
Injury ?accidental poisoning by other spec drug/medicament 
Injury ?accidental poisoning by drug or medicament NOS 




Acute hepatic failure 
Subacute hepatic failure 
Encephalopathy - hepatic 
Hepatic failure NOS 
Hepatitis unspecified NOS 
Hepatic infarction 
Toxic liver disease with hepatic necrosis 
Toxic liver disease with acute hepatitis 
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Acute hepatic failure due to drugs 
Nonspecific reactive hepatitis 
Hepatic failure as a complication of care 
Haemorrhagic nephrosonephritis 
Henoch-Schonlein nephritis 
Acute proliferative glomerulonephritis 
Acute nephritis with lesions of necrotising glomerulitis 
Other acute glomerulonephritis 
Acute glomerulonephritis in diseases EC 
Acute exudative nephritis 
Acute focal nephritis 
Acute diffuse nephritis 
Other acute glomerulonephritis NOS 
Acute glomerulonephritis NOS 
Nephrotic syndrome with proliferative glomerulonephritis 
Nephrotic syndrome+membranoproliferative glomerulonephritis 
Nephrotic syndrome with minimal change glomerulonephritis 
Lipoid nephrosis 
Steroid sensitive nephrotic syndrome 
Nephrotic syndrome minor glomerular abnormality 
Nephrotic syndrome focal and segmental glomerular lesions 
Nephrotic syndrome diffuse membranous glomerulonephritis 
Nephrotic syn difus mesangial prolifertiv glomerulonephritis 
Nephrotic syn difus endocapilary proliftv glomerulonephritis 
Nephrotic syn diffuse mesangiocapillary glomerulonephritis 
Nephrotic syndrome dense deposit disease 
Nephrotic syndrome diffuse crescentic glomerulonephritis 
Nephrotic syndrome in diseases EC 
Nephrotic syndrome in diseases EC NOS 
Nephrotic syndrome with other pathological kidney lesions 
Nephrotic syndrome NOS 
Nephritis and nephropathy unspecified 
Nephropathy unspecified 
Focal membranoproliferative glomerulonephritis 
Anaphylactoid glomerulonephritis 
Nephritis unsp+OS membranoprolif glomerulonephritis lesion 
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Lobular glomerulonephritis NEC 
Mesangioproliferative glomerulonephritis NEC 
Mixed membranous and proliferative glomerulonephritis NEC 
Nephritis unsp+membranoprolif glomerulonephritis lesion NOS 
Tubulo-interstit nephritis not specif as acute or chron 
Unspecif nephr synd diff concentric glomerulonephritis 
Unspecified nephritic syndrome dense deposit disease 
Unsp nephrit synd diff endocap prolif glomerulonephritis 
Unsp nephrit synd diff mesang prolif glomerulonephritis 
Other nephritis and nephrosis unspecified 
Other nephritis and nephrosis in diseases EC 
Other exudative nephritis 
Other nephritis and nephrosis NOS 
Acute renal failure 
Acute drug-induced renal failure 
Other acute renal failure 
Acute renal failure NOS 
End stage renal failure 
End stage renal failure 
Renal impairment 
Impaired renal function 
Impaired renal function disorder 
Other impaired renal function disorder 
Acute interstitial nephritis 
Other impaired renal function disorder NOS 
Impaired renal function disorder NOS 
Acute nephritic syndrome 
Acute nephritic syndrome minor glomerular abnormality 
Acute nephritic syndrome focal+segmental glomerular lesions 
Acute nephritic syn diffuse membranous glomerulonephritis 
Acut neph syn diffuse mesangial prolifrative glomnephritis 
Ac neph syn difus endocaplry prolifrative glomerulonephritis 
Acute neph syn diffuse mesangiocapillary glomerulonephritis 
Acute nephritic syndrome dense deposit disease 
Acute nephrotic syndrm diffuse crescentic glomerulonephritis 
Acute nephrotic syndrm diffuse crescentic glomerulonephritis 
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Rapidly progressive nephritic syndrome 
Rapid progres nephritic syn focal+segmental glomerulr lesion 
Rapid progres neph syn diffuse membranous glomerulonephritis 
Rpd prog neph syn df mesangial prolifratv glomerulonephritis 
Rapid progres neph syn df endocapilary prolifv glomnephritis 
Rapid prog neph syn df mesangiocapillary glomerulonephritis 
Rapid progressive nephritic syndrome dense deposit disease 
Rapid progres nephritic syn df crescentic glomerulonephritis 
Recur+persist haematuria difus membranous glomerulonephritis 
Recur+persist haemuria df mesangial prolif glomerulnephritis 
Recur+persist hmuria df mesangiocapilary glomerulonephritis 
Recur+persist haematuria difus crescentic glomerulonephritis 
Renal tubulo-interstitial disorders in diseases EC 
Balkan nephropathy 
Drug/heavy-metal-induced tubulo-interstitial and tub conditn 
Analgesic nephropathy 
Nephropathy induced by other drugs meds and biologl substncs 
Nephropathy induced by unspec drug medicament or biol subs 
Toxic nephropathy not elsewhere classified 
End-stage renal disease 
Other specified nephritis nephrosis or nephrotic syndrome 
Nephritis nephrosis and nephrotic syndrome NOS 
Nephropathy NOS in pregnancy without hypertension 
Acute renal failure following labour and delivery 
Post-delivery acute renal failure unspecified 
Post-delivery acute renal failure - delivered with p/n prob 
Post-delivery acute renal failure with postnatal problem 
Post-delivery acute renal failure NOS 
Renal failure as a complication of care 
ECG: ventricular ectopics 
ECG: no ventricular arrhythmia 
ECG: ventricular tachycardia 
ECG: ventricular fibrillation 
ECG: supraventricular arrhythmia 
ECG: ventricular arrhythmia 





Ventricular fibrillation and flutter 
Cardiac arrest-ventricular fibrillation 
Ventricular fibrillation and flutter NOS 
Cardio-respiratory arrest 
Cardiac arrest with successful resuscitation 
Sudden cardiac death so described 
Cardiac arrest unspecified 
Ventricular premature depolarization 
Sinus arrhythmia 
Other cardiac dysrhythmias 
Re-entry ventricular arrhythmia 
Other cardiac dysrhythmia NOS 
Cardiac rhythm drug poisoning 
Cardiac rhythm drug poisoning NOS 
Cardiac complications of care 
Cardiac arrest as a complication of care 
Cardiac complication of care NOS 
Had a fit 
Fit - had one symptom 
Had a convulsion 
Convulsion - symptom 
Myoclonic seizure 
Epileptic seizures - atonic 
Epileptic seizures - akinetic 
Other specified generalised nonconvulsive epilepsy 
Generalised nonconvulsive epilepsy NOS 
Generalised convulsive epilepsy 
Epileptic seizures - clonic 
Epileptic seizures - myoclonic 
Epileptic seizures - tonic 
Grand mal seizure 
Other specified generalised convulsive epilepsy 
Generalised convulsive epilepsy NOS 




Fit (in known epileptic) NOS 
Convulsions in newborn 
Fits in newborn 
Seizures in newborn 
Accidental poisoning by other drugs acting on nervous system 
Accid. poisoning by other drugs acting on nervous system OS 
Accidental poisoning by drugs acting on nervous system NOS 
Sunburn 
Sunburn of first degree 
Sunburn of second degree 
Sunburn of third degree 
Photocontact dermatitis [berloque dermatitis] 
Drug phototoxic response 
Drug photoallergic response 
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